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Cystic fibrosis (CF) continues to be a premier disease model for genetics research by 
demonstrating many of the successes of molecular genetics research as well as the 
challenges still facing the genetics research community. Research in CF has elucidated 
the mechanisms underlying specific DNA variants that cause disease, leading to the 
development of modulator therapies that are able to very specifically and potently 
improve the function of specific variant versions of CFTR protein. The eventual goal of 
providing effective therapy to all individuals with CF will depend on the expansion of the 
approval of currently available drugs to all individuals who would benefit and the 
development of novel compounds to treat variants that are unresponsive to current 
modulators. These two goals will be dependent upon detailed molecular understanding of 
all variants found on disease associated alleles of CFTR. To this end, we have used 
cellular models to accurately measure CFTR function in vitro and to test the response of 
missense variants to CFTR small molecule drugs. The current outlook for treating CF is 
very optimistic as new modulators proceed through clinical trials and extend accessibility 
of therapies capable of treating the underlying cause of CF to a growing number of 
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Chapter 1. Introduction 
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1.1 Cystic fibrosis is caused by loss of function of the CFTR gene 
Cystic fibrosis (CF) is caused by loss of function of the Cystic Fibrosis 
Transmembrane Regulator (CFTR) gene and demonstrates autosomal recessive (AR) 
inheritance. CFTR is a member of the ATP Binding Cassette (ABC) protein family but is 
unique in that it is the only ABC transporter known to act as an ion channel [1], 
suggesting that CFTR has a highly specialized role. Moreover, most human cells do not 
express CFTR at detectable levels and recent studies have suggested that only certain 
subtypes of airway cells express CFTR [2]. This specialized role of CFTR is likely the 
reason that CFTR is the only gene that causes CF and that severe mutations in CFTR only 
cause CF; mutations in other genes, such as ENaC and CA12, may result in phenotypes 
which demonstrate some but not all characteristics with CF. This is in contrast to other 
Mendelian conditions for which multiple genes within related pathways may result in the 
same or similar phenotypes or cases when variants in a single gene can cause multiple 
disorders depending on the nature of the variant.  
Loss of CFTR function affects multiple major organ systems by disrupting fluid 
movement across epithelial tissue layers. This disruption causes chronic dehydration of 
the surface fluids of secretory epithelia which in turn results in chronic obstruction, 
infection, inflammation, and ultimate destruction of affected organs [3]. The most 
severely affected organs with regards to human pathophysiology are the lungs, pancreas, 
and the gastrointestinal tract; the sweat gland and vas deferens are also affected but have 
no impact on mortality. The uniform etiology of CF makes it an ideal model for 
molecular genetics research. Complete interrogation of CFTR sequence in individuals 
with CF should yield pathogenic variants in all individuals with CF and correction of 
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CFTR function should improve clinical outcomes for all individuals with CF. For these 
reasons, CF provides an ideal platform for molecular genetics research and many of the 
lessons learned from studying CF may be applied to many other genetic disorders.  
 
1.2 Many genetic variants have been identified in CFTR 
More than 2,000 variants have been identified in individuals with CF 
(www.genet.sickkids.on.ca/cftr/). The most common CF-causing variant is p.Phe508del 
(F508del) and accounts for approximately 70% of all disease causing alleles in the CF 
population. Consequently, 49% of individuals with CF have two copies of F508del and 
91% of individuals carry at least one copy of F508del. Recommended diagnostic panels 
by the American College of Medical Genetics (ACMG) included the 23 most common 
CF causing variants [4]; including F508del, this mutation panel encompasses 87% of CF 
causing alleles and so is able to identify both pathogenic alleles in approximately 75% of 
individuals with CF and one pathogenic allele in 98% of individuals [5]. Diagnostic 
panels designed to interrogate known disease-causing variants have expanded in recent 
years to include additional variants, but many diagnostic labs perform sequencing of the 
coding regions of CFTR. Sequencing allows for interrogation of every nucleotide position 
of CFTR, and not just the specific variants interrogated by panels, thus the number of 
interrogated positions has expanded from the common disease-causing variant (F508del) 
to the entire coding region of CFTR, and is likely to expand to include the entire gene in 
the future. Massively parallel next generation (Next Gen) sequencing has revolutionized 
genetic testing and molecular diagnostics for all genetic conditions by rapidly decreasing 
the time and cost of DNA sequencing, allowing for cost efficient sequencing of entire 
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genes, panels of genes, whole exomes, and whole genomes in many research and clinical 
settings. This has resulted in the accumulation of CFTR sequencing data of individuals 
with CF and CF related symptoms as well as individuals without CF via whole exome 
sequencing (WES) or whole genome sequencing (WGS) studies of other unrelated 
phenotypes. However, interrogation of the entire coding region has resulted in the 
identification of a significant number of variants of unknown consequence [6].  
The CFTR2 project (www.CFTR2.org) was established to collect genotype data 
from individuals with CF around the world to interpret the clinical implications of this 
large number of sequence variants. Concurrently, a centralized database was created to 
improve the annotation of DNA variants with respect to their disease liability [5]. To date 
the CFTR2 project has assembled data from nearly 90,000 individuals from CF patient 
registries around the world, has identified 1,641 variants, and has classified 322 variants 
as CF causing, benign, or of varying clinical consequence. This increase in the number of 
classified variants over the original 23 ACMG variants has increased the diagnostic yield 
to 97% of all alleles with a clinical interpretation and 94% of all individuals with CF who 
have both of their pathogenic alleles identified [www.CFTR2.org; Dec 2017]. Of the 
1,641 variants identified, 40% are predicted to result in amino acid substitutions, 36% are 
predicted to alter RNA processing (including premature termination and splice site 
variants), 3% are predicted to alter CFTR gene structure (including deletions, 
duplications, and rearrangements), 1% are predicted to impact promoter activity, 14% 
appear to be neutral and 6% have unknown effect [3]. Annotation of variants continues to 
progress with the eventual goal of the annotation of all DNA variants in CFTR for their 
disease liability.  
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Interpretation of sequence variants that do not cause disease or only cause disease 
in certain contexts is extremely difficult. The presence of a rare sequence variant in an 
affected individual does not imply that that variant is pathogenic. Hence, the challenge is 
in distinguishing pathogenic variants from benign variants. Demonstration of the 
pathogenicity of a variant, can be achieved by interrogation of the functional 
consequence in vitro or observation that a variant is exclusively found in affected or 
carrier individuals while simultaneously absent in unaffected individuals. Several 
databases currently exist for evaluating the natural variation found in the human 
population; gnomAD is currently the largest of these databases and has collected data 
from 140,000 WES and WGS samples [7]. These types of databases cataloging CFTR 
variants in the general human population will increase the rate of discovery of rare 
variants and in some cases aid in the interpretation of those rare variants.  
 
1.3 Disease liability of a CFTR variant is determined by its effect on CFTR function 
Categorization of sequence variants is not as simple as distribution into 
pathogenic and non-pathogenic as CF, like many genetic conditions, exist on a 
phenotypic spectrum of variable expressivity. Variable expressivity has been 
exceptionally difficult to account for in classification; the clinical spectrum of severe CF, 
mild CF, and CF related symptoms is an important factor for patients, yet most 
computational and experimental assays only assess variants in a binary manner as 
predicted to cause disease or not [8]. The largest category of coding variants, in both 
affected and unaffected populations, are missense variants. Thus, accurate evaluation of 
missense variants is one of the most important and one of the most challenging tasks of 
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molecular diagnostics. This has led to the classification of severe pathogenic variants but 
the majority of variants that cause mild disease or demonstrate incomplete penetrance are 
often impossible to classify and are labeled as “Variants of Unknown Significance” 
(VUS). Rare variants present a significant challenge because many rare variants do not 
cause disease but exist at population frequencies indistinguishable from pathogenic 
variants. Interpretation of genetic variants has lagged significantly in comparison to the 
rate at which variants are discovered [9,10] and repeated sequencing of CFTR has 
identified many genetic variants that have received a VUS classification because they 
cannot be interpreted based on population frequency alone.  
Functional studies are a broad classification of tests that aim to understand the 
consequences of the genetic variants found in an individual with disease. In biochemical 
genetics functional testing is primarily performed by measuring the activity of a 
metabolic enzyme isolated from a patient, thereby directly interrogating the in vivo 
function of the enzyme [11]. For CF, direct in vivo functional testing of CFTR activity 
takes the form of measurements of sweat chloride concentration or nasal potential 
difference (NPD) [12]. Sweat chloride and NPD have become robust diagnostic tests with 
the ability to detect CF as well as CF related disorders [13]. While these functional tests 
will confirm the presence of disease in an individual, they do not identify the genetic 
variant responsible for the phenotype. Sequencing will identify a portion, dependent on 
the platform used, of genetic variants carried by an individual and subsequent 
determination of the pathogenicity of those variants will often require in vitro studies.  
Analysis of CFTR function in vitro relies on the development of relevant model 
systems. Mouse models have been commonly used in genetics research for decades but 
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are unfortunately an unsuitable model for studying CF [14]. Other larger mammals, such 
as ferrets and pigs, better represent the complete CF phenotype but are more difficult and 
expensive to study and limit the size of possible studies. Cellular models and organoids 
are significantly cheaper and faster so have the advantages of scalability and 
reproducibility which are necessary to make detailed assessments of function. However 
cellular models do not permit study of organismal disease progression or study of tissue 
specific effects of CFTR deficiency. A perfect model system does not exist for CF, but 
each of the available systems offers utility for studying specific questions regarding 
CFTR biology and CF pathogenesis.  
Cellular models are especially useful for directly interrogating CFTR function 
under the assumption that all physiological manifestations of CF are a directly correlated 
with CFTR function, referred to as the presence of a strong genotype to phenotype 
correlation. Two cellular models utilized for in vitro study of CFTR function are Fischer 
Rat Thyroid (FRT) and CF Bronchial Epithelial (CFBE) cell lines engineered to express 
specific alleles of CFTR [5,8,15]. These cell lines express CFTR in a controlled manner 
and allow for measurement of CFTR function via chloride conductance by measuring 
short circuit currents (Isc). The results of these studies have been compared with clinical 
findings of individuals carrying the studied variants to aid in the interpretation of their 
disease liability [8]. These studies suggest that CFTR function measured by in vitro 
assays has the ability to predict the disease liability of individual CFTR variants in cases 
when clinical data is lacking, or sample sizes are too small to draw strong conclusions.  
 
1.4 Modulator therapies target specific molecular mechanisms of CFTR dysfunction 
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Understanding the functional consequences of genetic variants allows for 
development of therapies designed to specifically correct the molecular defect underlying 
each genetic variant. As the variants that cause CF have varied molecular effects [28], it 
follows that there could be a separate class of therapeutic for each molecular mechanism. 
This paradigm has been successful in recent years with the development of two classes of 
CFTR modulators that have been approved by the FDA for treatment of individuals with 
CF with certain genotypes. Potentiators increase CFTR function by increasing the 
frequency with which CFTR opens [29] while correctors stabilize CFTR folding and 
biogenesis [30].  
Ivacaftor was the first CFTR modulator therapy approved to treat CF and was 
approved for individuals who carried the p.Gly551Asp (G551D) gating variant. Approval 
for individuals carrying G551D was based on in vitro studies of FRT cells, Human 
Bronchial Epithelial (HBE) cells, and primary nasal epithelial cells [29] which led to 
clinical trials demonstrating clinical efficacy [31]. Ivacaftor approval expanded over the 
following 5 years to include 37 additional variants. The first label expansion was based 
on the combination of cellular [17] and clinical studies [18] of known gating variants. 
Further expansion was provided on the basis of cellular or clinical studies [22].  
Lumacaftor was the second modulator developed, and improves CFTR function 
by stabilizing CFTR biogenesis and was designed to target the common F508del variant 
since it presents a significant folding defect [30]. Unfortunately, lumacaftor alone was not 
found to be clinically effective for individuals homozygous for F508del [20]. However, 
when utilized in combination with ivacaftor, homozygous F508del individuals 
demonstrated clinical improvement [21]. A second corrector compound, tezacaftor, has 
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recently been shown to effectively treat F508del homozygotes and individuals with 
residual CFTR function when used in combination with ivacaftor [24,32].  
The development and application of potentiators and correctors has revolutionized 
care for individuals with CF and charged efforts to fully understand the molecular 
etiology of all CFTR variants so that individuals carrying those variants can be prescribed 
the most effective therapy. However, the approved variants are likely only a small 
fraction of variants that will respond positively to these modulators. Thus, identifying 
other responsive variants will provide therapy to additional individuals with CF much 
more quickly than developing new therapies specific to every remaining variant. Due to 
the extremely low frequency of most variants, clinical studies are mostly impractical as 
the few individuals who share a rare variant may be located in disparate parts of the 
world. However, preliminary data for the response of a rare variant to approved 
modulators can be collected by in vitro assays, including engineered cell lines [17,22,23]. 
Missense variants have been of particular interest to study in vitro to inform therapeutic 
decisions because in vitro assays can study many variants and test multiple potential 
effects at once.  
Many coding variants will result in multiple molecular deficiencies and our ability 
to predict all of the effects of coding variants remains relatively poor, making it difficult 
to assign complete functionality to many coding variants. However, CFTR biogenesis is 
not a fully efficient process, at least to the point that CFTR modulators are able to 
improve the function of WT CFTR [33,34]. Studies have shown that CFTR modulators 
have the ability to improve function of coding variants independent of molecular 
mechanism [22,23], as long as they permit production of some protein which can be 
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targeted by potentiators and corrector compounds. Thus, it is likely that the vast majority 
of coding variants that produce CFTR protein can be treated by combination therapy, by 
increasing the chances of addressing the specific defect conferred by a pathogenic variant 
as well as improving the efficiency of molecular processes that are not deficient. We have 
found that the most accurate indicator of protein production in an individual with CF is 
the presence of moderated symptoms, suggesting that most individuals who have 
moderate phenotypes should demonstrate positive response to CFTR modulators. This 
concept has been shown in a clinical trial of individuals carrying ‘Residual Function’ 
variants [24] and we have demonstrated this in vitro using CFBE and FRT cell lines [23]. 
For these reasons, we believe combination therapy to be the most efficient route to 

















Chapter 2. Functional Assays Are Essential for Interpretation 




Determining the phenotypic consequences of DNA variants in genes associated 
with disease is a major goal for genomic medicine [35]. Variants in the coding region of 
genes can have a variety of consequences that may affect RNA quantity or processing or 
may alter the sequence of the encoded protein. Missense changes account for ~38% of 
variants implicated in single-gene disorders [36] and are particularly challenging to 
interpret as they can produce a broad array of effects, ranging from loss of protein due to 
severe instability to no discernible consequence. Accordingly, missense variants can 
create a spectrum of phenotypic consequences that encompass both variable expressivity 
and incomplete penetrance of clinical features that constitute Mendelian disorders [37]. 
Interpreting whether missense variants are responsible for partial expressivity of single 
gene disorders is a major challenge in the clinical and research setting. Indeed, genetic 
testing is frequently requested to help diagnose individuals with incomplete features of a 
Mendelian condition. However, labeling missense changes as variants of unknown 
significance due to lack of functional information does not resolve diagnostic dilemmas. 
Expression of mutants in heterologous cell lines provides a versatile method for 
assessing the functional effect of a wide range of variants [22,38]. The American College 
of Medical Genetics and Genomics (ACMG) and the Association for Molecular 
Pathology (AMP) have recognized the importance and utility of heterologous expression 
systems, and have weighted the results of well-established functional testing heavily 
within their recommended pipeline for variant classification for all Mendelian diseases 
[10]. These groups emphasize that studies should be validated, reproducible, and robust, 
and are most helpful when they are reflective of the biological environment in which a 
 13 
variant operates. Importantly, the ACMG/AMP guidelines recommend that interpretation 
of functional testing occur within the context of other available information, thereby 
avoiding placing too much emphasis on data that, while valuable, may not completely 
reflect a variant’s behavior in vivo. 
Cystic fibrosis (CF) (MIM: 219700) is caused by variants that lead to reduced 
function of the CF Transmembrane conductance Regulator (CFTR) (MIM: 602421; 
NM_000492.3). Full expressivity of CF manifests as dysfunction of epithelial tissues in 
the lungs, pancreas, and sweat duct [12]. However, not all features are consistently 
present, thereby giving rise to phenotypes exhibiting partial expressivity that can be 
difficult to differentiate from other causes of lung and/or pancreatic disease [13]. 
Missense variants are commonly found in association with partial expressivity of CF, 
thereby providing an opportunity to evaluate the utility of functional assessment in this 
situation [39]. Because commonly-performed protein folding studies are poor predictors 
of overall function [22], we chose to evaluate chloride conductance to determine the 
functional consequences of 48 CFTR missense variants reported in individuals that 
exhibit full and partial expressivity of CF. We show that functional assessment informs 
variant annotation when full or partial expressivity is present and that uncertainty of 
variant effect can be re-interpreted in the context of variable expression of a phenotype. 
Finally, we illustrate the limitations of algorithms that predict the functional 
consequences of missense variants. 
 
2.2 RESULTS 
Establishing wild-type CFTR standards for mRNA level, protein quantity, and function  
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To approximate the native context of CFTR in the lungs and to enable repeated 
measures of the chloride channel function of CFTR, we studied CFTR variants that were 
stably expressed in a well-established human airway cell line (CF Bronchial Epithelia; 
CFBE41o-) [40]. To determine the degree to which variants altered function relative to 
wild-type CFTR (WT-CFTR), we independently derived 10 CFBE41o- cell lines 
expressing a single copy of wild-type CFTR cDNA. The level of CFTR mRNA expressed 
in each of the 10 cell lines varied, as previously reported in cell lines with single site 
integrations [22], as did the level of CFTR protein and CFTR function (Fig 2.1A-C; 
Table S3). Since mRNA expression in each CFBE cell line was stable over time [15], we 
assessed the degree of correlation between RNA level determined by quantitative reverse 
transcription PCR (qRT-PCR) and mature (band C) protein level assessed by quantitative 
Western blotting; the correlation was linear and robust (R = 0.92; p = 1.59x10-4; Fig 
2.1D, left panel). Likewise, CFTR protein level and CFTR function determined by short 
circuit measurement for each of the 10 lines show excellent linear correlation (R = 0.99, p 
= 1.5x10-7; Fig 2.1D, middle panel). Finally, mRNA levels and CFTR function correlate 
well (R = 0.94; p = 7.06x10-5; Fig 2.1D, right panel), indicating that CFTR mRNA 
levels could be used to normalize CFTR chloride currents among independent cell lines.   
 
Determining the function of CFTR mutants relative to wild-type 
To establish the relationship between mRNA level and function across the full 
range of WT-CFTR expression, we combined data from 14 additional cell lines with the 
prior 10 WT-CFTR cell lines (total 24) to derive the slope of the linear correlation 
between CFTR mRNA quantity and CFTR function (R = 0.84; p = 3.37x10-7; Fig 2.2A 
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and Table 2.S3). A minor correction was made so that the slope intersected with the 
origin, under the assumption that zero mRNA should correspond to zero CFTR chloride 
current since parental CFBE cells express no detectable CFTR mRNA and generate no 
CFTR chloride current. With the slope set at 100% WT-CFTR, we then calculated slopes 
representing 25%, 10%, and 1% WT-CFTR function across the range of observed mRNA 
expression in CFBE cells (Fig 2.2A). These functional levels were chosen as they reflect 
approximate thresholds that transition from fully expressive to partially expressive forms 
of CF with the 10% to 25% threshold representing the range at which most individuals 
escape life-limiting lung disease [41–47]. 
To ensure that expression level of CFTR variants are comparable to native tissues, 
the mean RNA levels of CFTR relative to the housekeeping gene HPRT1 were compared 
using qRT-PCR in the 24 WT-CFTR cell lines or by extracting data from RNA 
sequencing of a different WT-CFTR and a G551D-CFTR cell line (0.49 vs 0.57; p=0.44; 
Fig 2.S1A). Using the entire set of RNA sequencing data, we determined CFTR transcript 
levels relative to all other RNA transcripts in the CFBE cell lines and compared these 
levels to CFTR mRNA levels in primary tissues affected by CF (study accession numbers 
in Table 2.S2). The mean level of CFTR mRNA in the CFBE cell lines is higher than in 
bronchial and nasal epithelia while lower than its expression in the pancreas (Fig 2.S1B). 
By extrapolation to the qRT-PCR data, we concluded that CFTR mRNA levels in the 
WT-CFTR cell lines are within physiologic ranges of endogenous CFTR mRNA levels in 
airway and pancreatic epithelia.  
To better discern CFTR variants with low residual function, chloride channel 
current was plotted on a semi-log chart against CFTR mRNA level (Fig 2.2B). To 
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determine the function of CFTR bearing putative CF-causing variants as a fraction of 
WT, we normalized currents generated by CFTR mutants using the level of mRNA 
expression in each CFBE cell line. Four examples are presented. Independently-derived 
cell lines stably expressing F508del (c.1521_1523delCTT; p.Phe508del)-CFTR generated 
currents ranging from 0.5% to 1.4% of WT-CFTR with a mean of 0.9% WT-CFTR after 
normalization for mRNA level (Fig 2.2B). This estimate of function is consistent with the 
association of F508del with full expressivity of CF and measurement of F508del-CFTR 
function in Fischer Rat Thyroid (FRT) cell lines (0.2% WT) and in primary bronchial 
airway cells (range 0.5% to 3.4% in F508del/F508del individuals) [5,48–51]. CFBE cell 
lines stably expressing T338I (c.1013C>T; p.Thr338Ile)-CFTR generated currents 
estimated at 6.4% of WT. The residual function of T338I-CFTR is consistent with full 
expressivity of CF observed in individuals with this variant, albeit a less severe 
phenotype than observed with F508del [5,52]. Variant G622D (c.1865G>A; 
p.Gly622Asp) permitted higher levels of CFTR function at 18.2% of WT-CFTR, 
consistent with its partial expressivity [53]. Finally, the substitution of cysteine for 
phenylalanine at codon 508 (F508C [c.1523T>G; p.Phe508Cys]) had no reduction of 
CFTR function in two CFBE cell lines (mean 114% WT). F508C has been shown to have 
minimal effect on CFTR folding and function [54], consistent with evidence that F508C 
does not cause disease when found in healthy CF carriers of F508del [55].   
 
Functional assessment distributes variants according to expressivity and informs 
assignment of disease liability using expert annotation criteria 
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Forty-eight missense variants ranging from 0.002% to 0.042% frequency in the 
CF population were selected from the CFTR2 database (Table 2.1 and Table 2.S1). 
Twenty-nine variants are associated with clinically diagnostic elevations in sweat 
chloride concentration (≥60 mEq/L) and life-limiting lung disease, consistent with full 
expressivity of CF. The remaining 19 variants are associated with partial expressivity 
(elevated but non-diagnostic sweat chloride concentration [31-59 mEq/L] and variably 
present life-limiting lung disease). Four variants (F508del, G551D, I336K [c.1007T>A; 
p.Ile336Lys], and T338I) that have been extensively studied in other cell lines and/or 
primary cells were included to validate our functional assay (total 52 variants). None of 
the variants are predicted to cause aberrant mRNA splicing using CryptSplice and 
NNSplice algorithms, each demonstrated to have >80% sensitivity[19,56,57]. CFTR 
function of the 52 missense variants was determined in CFBE stable cell lines that were 
normalized for mRNA levels as shown above (Table 2.1; data for individual clones are 
reported in Table 2.S4).  
Twenty-one of the 29 variants associated with full expressivity generated less 
than 10% WT-CFTR function, a conservative threshold for the development of life 
limiting lung disease, and were assigned as CF-causing using expert annotation criteria as 
previously described [5]. Another 4 variants (P5L [c.14C>T; p.Pro5Leu], D110E 
[c.330C>A; p.Asp110Glu], F1099L [c.3297C>A; p.Phe1099Leu], and T1246I 
[c.3737C>T; p.Thr1246Ile]) reduced function to 10-25% of WT-CFTR, a range 
consistent with their less severe phenotype. Since expert annotation uses a highly 
conservative 10% threshold to define CF-causing, these 4 variants were assigned as 
varying clinical consequences (VCC). Of the 4 remaining variants observed in 
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individuals with full expressivity of CF, one (E588V [c.1763A>T; p.Glu588Val]) had 
27.5 ± 6% WT-CFTR function, which overlaps with the 10-25% WT-CFTR functional 
range described above and consistent with a less severe phenotype. However, the 
remaining three (V562I [c.1684G>A; p.Val562Ile], D836Y [c.2506G>T; p.Asp836Tyr], 
and S912L [c.2735C>T; p.Ser912Leu]) allowed 71.2-121.1% WT-CFTR function (Table 
2.1). Even though these variants were presumed disease-causing and were reported as 
such by  clinicians, functional evidence indicates that they are not deleterious. Notably, 
all three variants have been reported to occur as part of complex alleles (Table 2.S5) 
involving other known or likely deleterious variants in cis [26,58–60], hence potentially 
explaining their presence in individuals with CF. 
None of the 19 variants associated with partial expressivity of CF had less than 
10% WT-CFTR function, as expected (Fig 2.3). Five variants generated 10-25% WT-
CFTR function, consistent with variable disease presentation, and were assigned as VCC. 
However, 10 variants generated between 25 and 75% WT-CFTR function, which should 
be sufficient to escape life-limiting lung disease. Six of these 10 variants were reported in 
individuals with clinical features consistent with a diagnosis of CF and were 
characterized as VCC. The remaining 4 in this group were reported in individuals who 
did not have clinical features consistent with a diagnosis of CF; however, because they 
reduce CFTR function by more than 25%, their role in the development of CF disease 
processes is unclear and their disease liability is unable to be determined. A further 4 
variants associated with partial expressivity of CF had minimal to no effect on CFTR 
function (75-100% WT-CFTR) and were assigned as non CF-causing, including one 
variant (F508C) with previously-published evidence of lack of CF phenotype when 
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present in trans with F508del [55,61]. Of the 14 variants associated with >25% WT-
CFTR function, 8 are associated with previously-reported complex alleles (Table 2.S5), 
which complicates our ability to directly correlate variant function with phenotype. We 
suspect that the identification of these ‘indeterminate’ or ‘non CF-causing’ missense 
variants in individuals with CF may have led to the erroneous assumption that they were 
deleterious (http://www.genet.sickkids.on.ca). Thus, functional testing was informative 
for assessment of variants associated with full expressivity and essential for interpretation 
of variants found in individuals with partial expressivity of CF. 
 
Functional data informs assignment of disease liability using ACMG/AMP criteria 
Use of ACMG/AMP criteria for disease assignment, which incorporates evidence 
from a variety of sources, demonstrated good correlation with expert annotation (Table 
2.2; individual variant annotations in Table 2.S6). Inclusion of functional data in the 
ACMG/AMP algorithm enabled assignment of 4 VUS as likely pathogenic and 17 likely 
pathogenic variants could be assigned as pathogenic (Table 2.2, upper panel). At the 
other end of the spectrum, 2 of the 6 variants assigned as non CF-causing by CFTR2 
criteria could be moved from VUS to likely benign or from likely benign to benign. The 
ACMG/AMP criteria also distributed the 16 variants of varying clinical consequence 
more precisely when applying a 25% threshold for defining a deleterious variant. Thus, 
functional data were particularly useful for verifying and excluding pathogenicity, 
thereby improving the assignment of variants as fully expressive or benign. 
To confirm that ACMG/AMP classifications maintained good correlation with 
expert annotation for more common variants, we also applied the guidelines to the 74 
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missense variants previously characterized by the CFTR2 team, many of which occur 
more frequently than those reported in this manuscript and some of which have been 
widely studied by other groups. ACMG/AMP annotations were reviewed by a CAP-
accredited and CLIA-certified clinical laboratory director with multiple years of 
experience in variant classification (M.B.S). Excellent correlation between ACMG/AMP 
and CFTR2 annotation was again observed, with all 50 CF-causing variants being 
assigned as pathogenic or likely pathogenic and 10 of 11 non CF-causing variants being 
assigned as benign or likely benign using ACMG/AMP guidelines when functional data 
was considered (Table 2.2, lower panel; individual variant annotations in Table 2.S6). 
Inclusion of functional data again enabled distribution of the variants annotated as 
causing varying clinical consequences and confirms its utility in determining 
pathogenicity. 
 
Algorithms fail to distinguish variants associated with variable expressivity  
To assess the ability of algorithms to predict the effect of the missense variants 
upon protein function, we evaluated four methods (CADD, REVEL, SIFT, and 
PolyPhen-2) commonly used in diagnostic and research settings. To ensure that variant 
scores for CADD and REVEL could reliably predict well-studied, relatively common, 
fully penetrant missense variants as deleterious, we first tested 6 CFTR missense variants 
that are included in the ACMG-recommended panel of CF-causing variants (A455E 
[c.1364C>A; p.Ala455Glu], G551D, G85E [c.254G>A; p.Gly85Glu], N1303K 
[c.3909C>G; p.Asn1303Lys], R334W [c.1000C>T; p.Arg334Trp], and R347P 
[c.1040G>C; p.Arg347Pro]). All six variants exceeded the recommended threshold score 
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for assignment as deleterious by CADD (PHRED score of 15) and scored highly (mean 
score of 0.88 out of 1) using REVEL, which does not have a specific recommended 
cutoff for deleteriousness. Next, an additional 30 variants previously classified as CF-
causing [5] were scored as deleterious using CADD, confirming its ability to correctly 
predict CF-causing variants even at lower frequencies. This group of 30 and the 
previously-described 6 ACMG variants were used to determine the appropriate REVEL 
cutoff for deleterious, which was set at 0.659 (two standard deviations below the mean 
score of all 36 variants) and which corresponds to 62% specificity and 95% sensitivity 
[62] (Table 2.S7).   
We next scored the 48 missense variants functionally studied here using REVEL 
and CADD and used the thresholds described to assign pathogenicity. Two other 
commonly used methods that provide categorical assignments (SIFT and PolyPhen-2) 
were also employed (Table 2.3). Each method classified the majority of variants as 
deleterious (Table 2.4). Consequently, accuracy was quite high when calling variants that 
reduced function below 10% of WT, the level at which full expressivity is present. 
Likewise, accuracy remained high if 25% of WT-CFTR function was used, although 
there is less evidence that reduction in function to between 10% and 25% is fully 
expressive for CF (see above). However, all four methods over-called variants as 
deleterious that were shown to have greater than 25% WT-CFTR function, leading to 
high numbers of false positives and low specificity, which ranged from 28% (REVEL) to 
6% (CADD). Finally, all four methods were inaccurate in predicting the consequences of 
the 6 variants that allowed CFTR to function in the normal range (>75% WT-CFTR) 
(Table 2.4). Two programs (CADD and SIFT) predicted all 6 variants to be deleterious 
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while REVEL and PolyPhen-2 predicted 5 of the 6 to be deleterious. Conversely, while 
false negative rates were low, SIFT was a notable exception as the algorithm called 6 of 
30 variants tolerated, even though functional testing found that 4 of the 6 had less than 
10% and the remaining 2 had less than 25% WT-CFTR function.   
To further assess the reliability of the predictive algorithms with variants known 
to be benign for CF, we also evaluated five relatively frequent CFTR variants which have 
minimal effect on function and multiple lines of evidence of non-penetrance. All four 
tools predicted at least 2 variants to be deleterious, meaning that they over-called 40% 
(SIFT and Poly-Phen2) or 60% (CADD and REVEL) of variants as deleterious though 
they are accepted as benign (Table 2.S8). Moreover, three of the five variants (G576A 
[c.1727G>C; p.Gly576Ala], R668C [c.2002C>T; p.Arg668Cys], and S1235R 
[c.3705T>G; p.Ser1235Arg]) were inconsistently predicted by the four tools; only one 
variant (V470M [c.1408G>A; p.Val470Met]) was consistently and correctly deemed 
non-deleterious and another (R75Q [c.224G>A; p.Arg75Gln]) was consistently but 
incorrectly deemed deleterious by all four tools. 
 
2.3 DISCUSSION 
As the number of identified variants continues to increase, interpretation of 
missense variants and their contribution to expressivity of Mendelian diseases presents a 
growing challenge to both researchers and clinicians. To inform this process, broader use 
of laboratory-based functional assays has been advocated [10,63]. Wide application of 
functional tests could increase the accuracy of variant interpretation in genes with both 
known and unknown association with disease, generate information and reagents 
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necessary for testing therapeutic agents, and inform the development of analytic tools for 
predicting variant effect [35]. Each of the aforementioned benefits was evident from our 
analysis of 48 CFTR missense variants associated with variable expressivity of CF.  
Assaying effects of missense variants upon protein function is a well-established 
approach to interpreting disease liability [64,65]. A desirable situation is to test mutant 
function in primary cells obtained from subjects, but this is challenging because: 1) 
samples are not easily collected from difficult-to-access tissues; 2) extremely rare 
variants may exist only in a few individuals worldwide; 3) primary cells undergo few cell 
divisions, limiting culturing and expansion; and 4) individual factors (e.g. background 
variation in the cellular genome) may confound the interpretation of variant effect. 
Together, these factors limit the number of variants that can be reliably measured in 
primary cells. High-throughput assays that utilize uniform measures of function, such as 
assessments of enzyme activity or protein binding, are useful for testing many variants 
but may not provide detailed functional information for non-soluble proteins or those 
with complex functions [66,67]. Most non-secreted proteins can be analyzed in cell-based 
systems that discern severity of defect by comparing the mutant function to wild-type 
[68]. Thus, heterologous cell-based systems provide a viable option for variant 
interpretation in the research and potentially the clinical laboratory [6,26]. Such systems 
are not without challenges; transient expression of mutants may have variability in 
transfection rates, cell growth, and other factors that lead to significant differences in 
expression level and complicate assessment of mutant function. As shown here, many of 
these problems can be addressed in systems that enable stable expression of a mutant. 
 24 
Numerous CFTR mutants have been functionally assessed by stable expression in 
Fischer Rat Thyroid (FRT) cells; this system has garnered FDA approval for drug label 
expansion to new variants. While FRT cells have provided a useful platform, they are 
from a different species and tissue type than human airway epithelia, in which CFTR 
defects cause life-shortening lung disease. For this reason, we elected to use a CF airway 
epithelial cell line shown to be a viable substitute for primary airway cells [15,69,70]. By 
using isogenic cell lines stably expressing CFTR, we were able to normalize for the level 
of expression among cell lines. This step was critical to interpreting partially functional 
variants expressed at different levels among individual clones. Without this 
normalization, minimally functional variants expressed at high levels and high-
functioning variants expressed at low levels could appear to have the same effect on 
function. Our approach to functional studies can be applied to almost any protein of 
interest since many different cell lines with targetable integration sites are available from 
academic and commercial sources. 
Functional characterization revealed expected and unexpected results. Thirty 
variants associated with full or partial expressivity of the CF phenotype generated 25% or 
less WT-CFTR function. This result is consistent with our current understanding of the 
level of CFTR function associated with a CF phenotype [44–47]. Notably, the 21 variants 
with less than 10% WT-CFTR function were associated with full expressivity of CF. 
Conversely, 6 of 48 variants did not affect the assayed function of CFTR, despite being 
reported as putative disease-causing variants in individuals with CF. With no meaningful 
reduction in function, these variants are likely in cis with other deleterious variants that 
may be unidentified by the genotyping methodology used. Indeed, 5 of the 6 variants 
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with function >75% WT-CFTR exist in cis with known or likely deleterious CFTR 
variants [26,59,60,71]. This observation emphasizes that individuals with an 
unambiguous clinical diagnosis of a recessive loss-of-function disorder who carry high-
function variants should have sequencing and deletion/duplication analysis to search for 
deleterious in cis variants. Evaluation of a variant found to exist as part of a complex 
allele may warrant further functional studies to accurately assess overall allele 
contribution to disease. 
In the absence of other deleterious in cis changes, alternative mechanisms of 
action not detectable by our methodology should be considered for missense variants 
with minimal reduction in chloride conductance. It is possible that these variants affect an 
untested function of CFTR such as bicarbonate transport, as seen in individuals 
presenting with pancreatitis [72]. However, the clinical features of some individuals 
bearing these variants are consistent with CF and all are followed by a CF specialty care 
center. We also believe that all variants should demonstrate the same relationship 
between mRNA level and CFTR function as WT-CFTR (as suggested by Fig 2.2), and 
that none of the missense variants tested had a significant impact on mRNA stability, 
though this mechanism has been suggested by others studying a synonymous change at 
codon 507 [73]. Another possibility is an effect on translation speed by use of rare 
tRNAs, as shown with the synonymous change T854T (c.2562T>G; p.Thr854T) [74], or 
up- or down-regulation of other genes resulting from changes within CFTR [75]; 
however, these effects are rarely reported to result from amino acid substitutions. Given 
the relative frequency of in cis changes within CFTR, complex alleles remain the most 
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likely explanation for the observation of variants with high function in individuals with 
CF [26,59,60,71].  
Twelve variants caused a modest decrease in CFTR function (25% to 75% of 
WT-CFTR), a level generally viewed as not causative for CF, but which may be 
influenced by other factors and result in partially or fully expressive CF in some 
individuals. Emerging data, such as the presence of additional in cis variants reported in 
the literature for 5 of these 12 variants, or that genetic and/or environmental modifiers 
conspire to the development of a range of CF symptoms when CFTR function is 
modestly compromised [76], may aid in further refinement of disease liability in the 
future. These findings illustrate that functional studies can disclose unexpected 
discrepancies that require further investigation to explain mechanism of disease and 
prevent mis-assignment of disease liability, even in a well-studied disorder such as CF. 
Functional analysis is likely to be of equal or potentially greater utility for more recently 
discovered disease-associated genes[64,65]. 
The ACMG/AMP guidelines for the interpretation of sequence variants generally 
had good correlation with expert annotation, particularly for variants with <25% WT-
CFTR function. However, one must carefully define the phenotype of interest so that the 
terms ‘pathogenic’ and ‘benign’ are used appropriately. For example, a variant associated 
with a CFTR-related disorder such as isolated male infertility could be deemed 
pathogenic for that phenotype, but may be benign in the context of fully expressive CF 
[77]. Clinical laboratories are often not provided detailed phenotype information, making 
it challenging to decide in what disease context to evaluate a variant [6]. Indeed, an 
investigation into annotation discrepancies identified functional data and population data 
 27 
as frequent contributors to differing interpretations [78]. Our study also revealed that 
correlation between ACMG/AMP and CFTR2 annotation is incomplete since there is no 
defined category for variants causing partial expressivity using ACMG/AMP guidelines. 
CFTR2 uses the term ‘varying clinical consequence’ for variants that may cause CF in 
some people but not others, but which typically have enough of a functional deficit that 
they cannot be considered non CF-causing. As shown here, these variants have reduced 
CFTR function and are associated with CFTR-related symptoms that do not meet the 
diagnostic criteria for CF in all individuals bearing them. If CF is the defined phenotype 
for which ACMG/AMP guidelines are being applied, it may be difficult to assign these 
variants as pathogenic or likely pathogenic (without clear evidence of CF in some 
people), but the term VUS is not appropriate because, in many cases, clinical significance 
is not uncertain. A similar dilemma is faced in annotation of BRCA2 variants in which a 
probability threshold and annotation for deleterious variants associated with only 
moderate risk for cancer have yet to be determined [79].  The ongoing challenge of 
annotation of variants with moderate functional effects lends itself well to the 
incorporation of quantitative functional results and their associated endophenotypes 
(continuous-valued quantitative traits) [80] into a variant classification scheme. 
Considerable effort has been devoted to the development of computational tools 
that predict variant effect. Most tools consider evolutionary conservation, properties of 
the native and variant amino acids and their possible impact on structure and stability, or 
both [81]. Machine learning using a subset of annotated variants can incorporate more 
and varied types of information, but is limited by data quality, quantity, and relevance of 
the training set, often leading to low sensitivity, low specificity, and incongruent variant 
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calls [79,82–84].  The in silico tools evaluated here, selected because they are either 
commonly used individual predictors (SIFT and PolyPhen-2) [85] or are more recently-
developed ensemble predictors (CADD and REVEL), had good performance for 
functionally deleterious variants that lead to full expressivity of CF. However, they could 
not discern functional levels that distinguish full from partial expressivity of CF. The 
main issue lies within the binary output of most models, which predict whether or not a 
variant has an effect but not its magnitude [86]. This likely leads to the over-calling of 
benign variants as deleterious, some of which may minimally affect protein function but 
at a level that does not impact phenotype. When we compared functional results and 
disease liability assignments to the variant effect predictions of four in silico tools, we 
found that the tools overestimate deleteriousness, a trend also seen in other genes with 
well-annotated or functionally-assessed  variants [79,87,88]. In the current exome and 
genome sequencing era, clinicians and researchers using these in silico tools to assess the 
pathogenicity of missense variants discovered in putative disease-causing genes in the 
absence of other supporting data should be cautious[6,89]. 
In summary, investigation into the effects of 48 missense variants in CFTR has 
filled a gap in knowledge regarding the function associated with partial expressivity of a 
recessive Mendelian phenotype. This work will also inform the testing of newly-
developed therapeutics on rare CFTR variants that are not well-suited for clinical trials.   
 
2.4 Materials and Methods 
Selection of CFTR variants 
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CFTR variants for study were selected from de-identified demographic and 
clinical data collected by the CFTR2 project from 88,664 individuals currently or 
previously alive and followed by a CF specialty center in 41 countries. Data were 
provided by national CF patient registries and by major clinical centers in countries with 
no registry (Table 2.S1 [contributors of variants reported in this manuscript] and 
Acknowledgments [all CFTR2 contributors]). CFTR genotype and sweat chloride 
concentration were obtained from the individual’s clinical record as previously reported 
[5]. Missense variants of unknown effect were selected for study if they were reported in 
at least three individuals in the CFTR2 database and if the average sweat chloride 
concentration of individuals bearing the variant of interest in trans with a severe CF-
causing variant fell within a range of minimal to moderate elevation of 31 to 102 mEq/L. 
RNA sequencing analysis 
RNA sequencing raw reads of CF bronchial epithelial (CFBE) cells expressing 
wild-type CFTR (WT-CFTR) and G551D (c.1652G>A; p.Gly551Asp)-CFTR [15] (n=6), 
pancreas (n=3), lung tissues (n=3), nasal epithelia (n=3), and ALI bronchial epithelia 
(n=3) were obtained from the National Center for Biotechnology Information (NCBI) 
Sequence Read Archive (SRA) database (study accession numbers in Table 2.S2). 
Transcripts were assembled and abundances were estimated with the Tuxedo software 
suite. Raw reads were mapped to the reference genome (hg19) with TopHat (v2.0.13), 
using Bowtie2 (version 2.1.0.0). Mapped sequences were assembled with Cufflinks 
(v2.2.1). CuffQuant was used to estimate the relative abundances of gene transcripts 
among samples and CuffDiff was then used to determine differential expression values 
 30 
among samples. For comparison with RT-PCR fold-change values, CFTR expression was 
measured as a fold-change relative to HPRT1 (CFTR FPKM / HPRT1 FPKM). 
Derivation and analysis of CFBE cell lines expressing CFTR variants 
Site-directed mutagenesis 
Site-directed mutagenesis of pEF5/FRT plasmid, utilizing human eF1α promoter 
coupled to WT-CFTR cDNA sequence, was performed using mutagenic primers designed 
using the Agilent QuikChange primer design website. PCR products were digested with 
Dpn1 to remove parental plasmid and then ethanol precipitated, rehydrated, and used to 
transform XL10-Gold Ultracompetent cells (Agilent). DNA minipreps were prepared 
(Denville Spinsmart Plasmid Miniprep DNA Purification Kit) and Sanger sequencing 
confirmed the presence of the variant of interest. Sequence-confirmed miniprep plasmid 
was used to transform DH5α competent cells (Invitrogen), and DNA maxipreps were 
prepared (Qiagen Plasmid Plus Maxi Kit). Sanger sequencing of the entire CFTR cDNA 
confirmed the presence of the variant of interest and the absence of secondary changes. 
Generation of human airway epithelial cell lines with integrated CFTR variants 
CF bronchial epithelial (CFBE41o-) cells containing a Flp Recombinase Target 
(FRT) integration site [15] were grown in complete media supplemented with 100μg/ml 
Zeocin (Gibco or ThermoFisher). Prior to transfection, cells were seeded in collagen-
coated 6-well plates and grown to >70% confluency. Collagen coating was achieved by 
applying a mixture of 5ml of 0.1% bovine serum albumin (MilliporeSigma), 500μl rat tail 
Collagen I (Life Technologies – 3mg/ml), and 500μl of human fibronectin (Sigma-Adrich 
– 1mg/mL) diluted in 44 ml MEM to each well, before aspirating the mixture and 
allowing the plates to dry for at least 1 hour. 0.5μg of CFTR plasmid combined with 
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4.5μg of pOG44 Flp-recombinase plasmid was transfected using Lipofectamine LTX 
(Life Technologies). Cells were incubated for 48 hours and then split 1:4 into collagen 
coated 6-well plates. Media was changed after 48 hours to include 50μg/ml Hygromycin 
B for 24-48 hours then changed again with media containing 100μg/ml Hygromycin B. 
Cells remained under Hygromycin selection until distinct clones were observed in 
transfection wells and all cells in mock-transfected wells had died. Individual clones were 
isolated using 8x8mm sterile cloning cylinders (Millipore) and grown in collagen-coated 
24-well plates until confluency, when they were expanded to uncoated vessels for 
characterization.  
Verification of CFTR cDNA integration by PCR 
Genomic DNA was extracted from Hygromycin-resistant cells using Qiagen 
DNeasy Blood & Tissue Kit and full length CFTR cDNA was PCR amplified to confirm 
plasmid integration. PCR of the Flp-In site was also performed to confirm disruption of 
the target FRT site. PCR fragments containing the sequence variant of each cell line were 
sequenced to confirm the presence of the variant in the genomic DNA of the cell line. 
Quantification of CFTR RNA by real-time PCR 
Total RNA was isolated from cultured cells on the same day short-circuit current 
(Isc) measurements were taken (see below). Cells were washed with PBS made with 
DEPC-treated H2O and lysed by addition of 250µl of TRIzol reagent (Life Technologies) 
followed by centrifugation through a shredder column (Denville). One hundred µl 
chloroform was added to cell lysates and were centrifuged at 12,000xg for 5 minutes at 
4C. Clear supernatant was kept for RNA purification using the Total RNA Mini 
Purification Kit (Denville). 500ng of total RNA was used to generate first strand cDNA 
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libraries using the iScriptTM cDNA Synthesis Kit (Bio-Rad). RNA and cDNA 
preparations were made each day that short circuit current measurements were taken. 
cDNA samples were amplified using SsoAdvanced Universal SYBR Green Supermix 
(Bio-Rad) on the CFX Connect Real-Time System (Bio-Rad). Two sets of PCR primers 
were designed to generate short fragments (121bp and 102bp) of CFTR cDNA which 
spanned exon-exon junctions. PCR primers for housekeeping genes were purchased from 
BioRad. Reactions were performed in triplicate for 30 cycles and ∆Ct was calculated for 
each sample.  
Quantification of CFTR protein by Western blot 
Whole cell lysate was purified from WT-CFTR CFBE stable cell lines using 
250µl of RIPA protein lysis buffer (MilliporeSigma) supplemented with 1% protease 
inhibitor cocktail (MilliporeSigma) and 0.1% serine protease inhibitor, PMSF 
(MilliporeSigma). Cells were further lysed by vortexing and lysates were collected after 
centrifugation. 100µg of protein lysate was diluted to 21µl in PBS and incubated with 7µl 
dye solution containing a 1:5 dilution of DTT to 4X Laemmli Sample Buffer (BioRad) at 
37C for 15 minutes. Samples were run in a 7.5% Tris-HCl, 1.0 mm BIO-RAD Criterion 
Precast Gel with running buffer composed of 25mM Tris, 250mM electrophoresis grade 
glycine (pH 8.3), 0.1% SDS in dH2O. Protein was transferred to a PVDF membrane by 
electrophoresis using the Trans-Blot Turbo Transfer System (BioRad) at 2.5A, 25V for 
10 minutes. Membranes were cut above the 100kDa band, reserving the upper half for 
visualization of CFTR protein and the lower half for visualization of Na+/K+-ATPase. 
Membranes were blocked for one hour in 5% non-fat dry milk reconstituted in PBS 
containing 0.1% tween-20 (PBST). Membranes were washed in PBST and then incubated 
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for 1 hour at room temperature with primary antibody: anti-CFTR m596 antibody (UNC) 
diluted 1:1000 or anti-Na+/K+ antibody (abcam – ab76020) diluted to 1:100,000. Primary 
antibody was removed by washing with PBST for 30 minutes. Membranes were 
incubated for 1 hour at room temperature with secondary antibody: anti-mouse (CFTR) 
(GE Healthcare) diluted 1:150,000 or anti-rabbit (Na+/K+) (GE Healthcare) diluted 
1:150,000. Secondary antibody was removed by washing with PBST for 45 minutes. 
Membranes were imaged on high performance chemiluminescence film (GE Healthcare) 
using ECL Prime Detection Reagent (GE Healthcare) and the Kodak X-Omat 2000A 
Processor. 
CFTR protein was quantified using the ImageJ software by dividing the intensity 
of CFTR C-band by the intensity of the Na+/K+-ATPase band for exposures that had not 
reached saturation. CFTR protein quantity represents an average of 3 of Western blots, 
with 5-21 exposures measured for each cell line. 
Assessment of CFTR function by short-circuit current measurement 
1x105 cells were plated onto Snapwell filters (12 mm filter diameter with 0.4 µm 
pore diameter; Corning Costar #3407) for 6 days with daily feeding, resulting in a 
transepithelial resistance of at least 200Ω∙cm2, although the specific resistance achieved 
was variable between cell lines. Filters were mounted into Ussing chambers and short 
circuit currents (Isc) were measured with a VCC MC6 or VCC MC8 multichannel 
voltage-current clamp amplifier (Physiologic Instruments). Asymmetric apical and 
basolateral buffers were used to create a chloride gradient, with the apical buffer 
composed of 145mM NaGluconate, 1.2mM MgCl2, 1.2mM CaCl2, 10mM dextrose, and 
10mM HEPES, and the basolateral buffer composed of 145mM NaCl, 1.2 MgCl2mM, 
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1.2 CaCl2mM, 10mM dextrose, and 10mM HEPES. Buffers were maintained at 37°C and 
air was bubbled in to introduce circulation. After stabilization of transepithelial current, 
10µM forskolin (Selleckchem) was added to the basolateral chamber to stimulate 
generation of cAMP and activation of CFTR, followed by administration of 10µM CFTR 
inhibitor-172 (Selleckchem) in the apical chamber to block CFTR-mediated currents. 
Data were acquired with the software Acquire and Analyze (Physiologic Instruments). Isc 
changes (ΔIsc) were calculated by taking the difference in the Isc recorded after adding 
Inh-172.  
In silico prediction models and ACMG/AMP classification criteria 
Four in silico prediction models were applied to determine the predicted effect of 
missense variants on protein function: CADD [90], REVEL [62], SIFT [91], and 
PolyPhen-2 (HumVar model) [92]. These programs were accessed via their respective 
online tools. CADD and REVEL had specific thresholds for deleteriousness applied 
(CADD PHRED score of 15, as recommended by the program developers, and REVEL 
score of 0.659, as determined by a subset of previously-defined CF-causing variants). 
SIFT and PolyPhen-2 distinguish between damaging and tolerated and benign, possibly 
damaging, and probably damaging, respectively.  All missense variants (total 122), 
including those reported in this manuscript and those previously-published on the CFTR2 
website, were also characterized according to the ACMG/AMP variant classification 
guidelines as pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, 
or benign [10]. Interpretations were assigned with and without the inclusion of functional 





Figure 2.1 CFTR mRNA, protein level, and function are variable but correlated. 
(A) Mean and standard deviations of CFTR mRNA transcript quantity relative to HPRT1 
(n =3 for each cell line) for 10 independent cell lines expressing WT-CFTR. (B) Western 
blot detecting varying quantities of mature (Band C) CFTR protein from whole cell 
lysates of 10 cell lines expressing WT-CFTR. Controls include cell lines expressing the 
CF-causing variants F508del that causes a folding defect (Band B only) and G551D 
(Band C), non-transfected CFBE cells (no signal), and WT-CFTR transiently expressed in 
HEK293 cells (Band C). Loading controls for protein quantity (Na+/K+ ATPase) are 
shown below. Plot on right shows mean and standard deviations of CFTR protein 
quantities for each cell line relative to the WT-CFTR 5 cell line assessed from at least 3 
Western blots. (C) Representative recordings of CFTR function measured by Isc for 10 
WT-CFTR cell lines. Forskolin (10 µM) activates CFTR chloride current and the amount 
of current inhibited by the CFTR-specific inhibitor inh-172 (10 µM) determines the level 
of CFTR function. Plot on right shows mean and standard deviations for Isc derived from 
at least 3 measurements for the 10 WT-CFTR cell lines. (D) Correlations of the quantity 
of CFTR mRNA with quantity of mature CFTR protein (left panel); quantity of mature 
CFTR protein with CFTR function (center panel); and quantity of CFTR mRNA with 
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Figure 2.2 Independently derived cell lines of CFTR missense variants yield 
consistent interpretation.  
(A) Standard curve (dashed line) for 100% WT-CFTR function derived using CFTR 
mRNA and CFTR function from 24 independent cell lines expressing WT-CFTR. 
Predicted CFTR function corresponding to 25% (green), 10% (gold), and 1% (red) of 
WT-CFTR function across the range of mRNA expression observed in WT-CFTR cell 
lines. (B) Plot of log CFTR function against CFTR mRNA quantity derived from 
correlation shown in (A). After normalization for mRNA levels, CFTR variants 
expressed in multiple independent cell lines show consistent levels of residual CFTR 





Figure 2.3 Distinct distributions of the residual CFTR function of variants 
associated with full or partial expressivity of CF.  
The majority of variants associated with full expressivity of CF allow less than 10% WT-
CFTR function while the remainder distribute across three higher ranges of function. 
None of the variants associated with partial expressivity of CF have less than 10% CFTR 
function.  
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Table 2.1 Functional results and disease liability determination for missense variants  
Variant 
(legacy)  Variant (cDNA)  Variant (protein)  
n alleles in 
CFTR2  
Allele freq. in 
CFTR2  
Mean sweat [Cl-





Variants with function <10% WT-CFTR 
F508del  c.1521_1523delCTT  p.Phe508del  98735  69.856%  ≥60  0.7 ± 0.4  CFb 
W57G  c.169T>G  p.Trp57Gly  10  0.007%  ≥60  1 ± 0.2  CF  
L558S  c.1673T>C  p.Leu558Ser  34  0.024%  ≥60  1.2 ± 1.6  CF  
Y563D  c.1687T>G  p.Tyr563Asp  7  0.005%  ≥60  1.3 ± 0.7  CF  
Y563N  c.1687T>A  p.Tyr563Asn  33  0.023%  ≥60  1.9 ± 1  CF  
H609R  c.1826A>G  p.His609Arg  10  0.007%  ≥60  2.2 ± 0.4  CF  
A613T  c.1837G>A  p.Ala613Thr  6  0.0042%  ≥60  2.3 ± 0.9  CF  
L1335P  c.4004T>C  p.Leu1335Pro  19  0.013%  ≥60  2.4 ± 1.2  CF  
I336K  c.1007T>A  p.Ile336Lys  55  0.0389%  ≥60  2.4 ± 0.7  CFb 
L165S  c.494T>C  p.Leu165Ser  21  0.015%  ≥60  2.7 ± 1.3  CF  
G551D  c.1652G>A  p.Gly551Asp  2984  2.111%  ≥60  2.9 ± 1.6  CFb 
P574H  c.1721C>A  p.Pro574His  25  0.018%  ≥60  3 ± 0.5  CF  
A1006E  c.3017C>A  p.Ala1006Glu  8  0.0057%  ≥60  3.4 ± 1.5  CF  
R334L  c.1001G>T  p.Arg334Leu  15  0.011%  ≥60  3.6 ± 0.9  CF  
P99L  c.296C>T  p.Pro99Leu  7  0.005%  ≥60  3.6 ± 0.8  CF  
V456A  c.1367T>C  p.Val456Ala  27  0.019%  ≥60  4.1 ± 1.4  CF  
S1159F  c.3476C>T  p.Ser1159Phe  13  0.009%  ≥60  4.7 ± 0.5  CF  
D513G  c.1538A>G  p.Asp513Gly  7  0.005%  ≥60  4.8 ± 1.7  CF  
Q98R  c.293A>G  p.Gln98Arg  16  0.011%  ≥60  5.4 ± 0.7  CF  
S1118F  c.3353C>T  p.Ser1118Phe  7  0.005%  ≥60  5.8 ± 3.1  CF  
T338I  c.1013C>T  p.Thr338Ile  52  0.0368%  ≥60  6.4 ± 0.8  CFb 
R1283M  c.3848G>T  p.Arg1283Met  7  0.005%  ≥60  6.7 ± 3.9  CF  
E116K  c.346G>A  p.Glu116Lys  8  0.006%  ≥60a 6.7 ± 2  CF  
D979V  c.2936A>T  p.Asp979Val  3  0.002%  ≥60  7 ± 3.7  CF  
F311L  c.933C>G  p.Phe311Leu  9  0.006%  ≥60  7.6 ± 3.3  CF  
Variants with function 10 to <25% WT-CFTR 
T1246I  c.3737C>T  p.Thr1246Ile  23  0.016%  ≥60  12.9 ± 4.1  VCC  
F1099L  c.3297C>A  p.Phe1099Leu  7  0.005%  ≥60  15.1 ± 6.4  VCC  
F575Y  c.1724T>A  p.Phe575Tyr  7  0.005%  <60  17.1 ± 3.1  VCC  
G622D  c.1865G>A  p.Gly622Asp  8  0.006%  <60  18.2 ± 0.4  VCC  
V1153E  c.3458T>A  p.Val1153Glu  6  0.004%  <60  18.7 ± 5.6  VCC  
M265R  c.794T>G  p.Met265Arg  7  0.005%  <60  19.1 ± 1.9  VCC  
D110E  c.330C>A  p.Asp110Glu  14  0.010%  ≥60  19.9 ± 4.6  VCC  
Y1032C  c.3095A>G  p.Tyr1032Cys  16  0.011%  <60  20.6 ± 4.7  VCC  
P5L  c.14C>T  p.Pro5Leu  60  0.042%  ≥60  22.4 ± 3.1  VCC  
Variants with function 25 to 75% WT-CFTR 
R334Q  c.1001G>A  p.Arg334Gln  8  0.006%  <60  26.6 ± 4.2  VCC  
E588V  c.1763A>T  p.Glu588Val  6  0.004%  ≥60  27.5 ± 6  VCC  
R117G  c.349C>G  p.Arg117Gly  8  0.006%  <60  34.7 ± 4.7  VCC  
A349V  c.1046C>T  p.Ala349Val  11  0.008%  <60  44.9 ± 10.3  IND  
V201M  c.601G>A  p.Val201Met  11  0.008%  <60  47.5 ± 15.1  IND  
P750L  c.2249C>T  p.Pro750Leu  13  0.009%  <60  48.6 ± 6.6  VCC  
D443Y  c.1327G>T  p.Asp443Tyr  8  0.006%  <60  53.2 ± 10.8  VCC  
R31L  c.92G>T  p.Arg31Leu  7  0.005%  <60  56.3 ± 16  IND  
Q1291R  c.3872A>G  p.Gln1291Arg  9  0.006%  <60  62.3 ± 43.3  VCC  
S912L  c.2735C>T  p.Ser912Leu  6  0.004%  ≥60  71.2 ± 18.2  IND  
Y1014C  c.3041A>G  p.Tyr1014Cys  6  0.004%  <60  73.8 ± 27.7  IND  
L967S  c.2900T>C  p.Leu967Ser  20  0.014%  <60  74.4 ± 12.2  VCC  
Variants with function >75% WT-CFTR 
T1053I  c.3158C>T  p.Thr1053Ile  9  0.006%  <60  78.8 ± 27.2  Non CF  
F508C  c.1523T>G  p.Phe508Cys  8  0.006%  <60  114 ± 20.1  Non CF  
I807M  c.2421A>G  p.Ile807Met  9  0.006%  <60  115.2 ± 27  Non CF  
V562I  c.1684G>A  p.Val562Ile  20  0.014%  ≥60  116.4 ± 30.5  Non CF  
D836Y  c.2506G>T  p.Asp836Tyr  9  0.006%  ≥60  122.1 ± 36.4  Non CF  
R170H  c.509G>A  p.Arg170His  11  0.008%  <60  150.4 ± 97.1  Non CF  
aSweat chloride value is based on n=2, which is below CFTR2 standards (minimum requirement of sweat chloride n = 3) to use as clinical 
evidence for disease. Consequently, this variant will not be published on the CFTR2 website.  
bVariant disease liability previously determined and published in Sosnay et al. [5]  




Table 2.2 Comparison of variant annotation using ACMG/AMP criteria (with and without inclusion of 




functional data in 
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aFunction was incorporated using different thresholds for pathogenicity; 10% (more conservative, considered the threshold for life-limiting lung 























score  SIFT  PolyPhen-2  
Variants with function <10% WT-CFTR 
W57G  c.169T>G  p.Trp57Gly  CF  1.0  29.9  0.834  Damaging  Benign  
L558S  c.1673T>C  p.Leu558Ser  CF  1.2  30  0.98  Damaging  Probably  damaging  
Y563D  c.1687T>G  p.Tyr563Asp  CF  1.3  31  0.975  Damaging  Probably damaging  
Y563N  c.1687T>A  p.Tyr563Asn  CF  1.9  31  0.969  Damaging  Probably damaging  
H609R  c.1826A>G  p.His609Arg  CF  2.2  18.85  0.809  Tolerated  Probably damaging  
A613T  c.1837G>A  p.Ala613Thr  CF  2.3  24.9  0.83  Tolerated  Probably  damaging  
L1335P  c.4004T>C  p.Leu1335Pro  CF  2.4  29  0.948  Damaging  Probably damaging  
L165S  c.494T>C  p.Leu165Ser  CF  2.7  27.4  0.929  Damaging  Probably damaging  
P574H  c.1721C>A  p.Pro574His  CF  3.0 32  0.98  Damaging  Probably damaging  
A1006E  c.3017C>A  p.Ala1006Glu  CF  3.4  23.2  0.58  Damaging  Benign  
R334L  c.1001G>T  p.Arg334Leu  CF  3.6  23.2  0.726  Damaging  Probably damaging  
P99L  c.296C>T  p.Pro99Leu  CF  3.6  34  0.945  Damaging  Probably damaging  
V456A  c.1367T>C  p.Val456Ala  CF  4.1  25.4  0.916  Damaging  Possibly damaging  
S1159F  c.3476C>T  p.Ser1159Phe  CF  4.7  33  0.919  Damaging  Probably damaging  
D513G  c.1538A>G  p.Asp513Gly  CF  4.8  24.2  0.963  Damaging  Probably damaging  
Q98R  c.293A>G  p.Gln98Arg  CF  5.4  27.1  0.946  Damaging  Probably damaging  
S1118F  c.3353C>T  p.Ser1118Phe  CF  5.8  25  0.085  Damaging  Probably damaging  
R1283M  c.3848G>T  p.Arg1283Met  CF  6.7  33  0.962  Damaging  Probably damaging  
E116K  c.346G>A  p.Glu116Lys  CF  6.7  26.5  0.782  Tolerated  Probably damaging  
D979V  c.2936A>T  p.Asp979Val  CF  7.0 28.7  0.985  Damaging  Probably damaging  
F311L  c.933C>G  p.Phe311Leu  CF  7.6  22.8  0.712  Tolerated  Possibly damaging  
Variants with function 10% to <25% WT-CFTR 
T1246I  c.3737C>T  p.Thr1246Ile  VCC  12.9  32  0.925  Damaging  Probably damaging  
F1099L  c.3297C>A  p.Phe1099Leu  VCC  15.1  23.3  0.619  Tolerated  Probably damaging  
F575Y  c.1724T>A  p.Phe575Tyr  VCC  17.1  29.6  0.868  Damaging  Probably damaging  
G622D  c.1865G>A  p.Gly622Asp  VCC  18.2  29.7  0.964  Damaging  Probably damaging  
V1153E  c.3458T>A  p.Val1153Glu  VCC  18.7  33  0.939  Damaging  Possibly damaging  
M265R  c.794T>G  p.Met265Arg  VCC  19.1  24.3  0.659  Damaging  Benign  
D110E  c.330C>A  p.Asp110Glu  VCC  19.9  16.39  0.733  Tolerated  Possibly damaging  
Y1032C  c.3095A>G  p.Tyr1032Cys  VCC  20.6  25.1  0.887  Damaging  Probably damaging  
P5L  c.14C>T  p.Pro5Leu  VCC  22.4  33  0.887  Damaging  Probably damaging  
Variants with function 25% to 75% WT-CFTR 
R334Q  c.1001G>A  p.Arg334Gln  VCC  26.6  19.78  0.692  Tolerated  Probably damaging  
E588V  c.1763A>T  p.Glu588Val  VCC  27.5  29.3  0.97  Damaging  Possibly damaging  
R117G  c.349C>G  p.Arg117Gly  VCC  34.7  26.4 0.773 Damaging  Probably damaging 
A349V  c.1046C>T  p.Ala349Val  IND  44.9  27.5  0.632  Tolerated  Possibly damaging  
V201M  c.601G>A  p.Val201Met  IND  47.5  27.1  0.676  Damaging  Possibly damaging  
P750L  c.2249C>T  p.Pro750Leu  VCC  48.6  22.9  0.655  Damaging  Benign  
D443Y  c.1327G>T  p.Asp443Tyr  VCC  53.2  26  0.83  Damaging  Possibly damaging  
R31L  c.92G>T  p.Arg31Leu  IND  56.3  22.9  0.546  Tolerated  Benign  
Q1291R  c.3872A>G  p.Gln1291Arg  VCC  62.3  23.2  0.871  Damaging  Benign  
S912L  c.2735C>T  p.Ser912Leu  IND  71.2  9.977  0.543  Tolerated  Benign  
Y1014C  c.3041A>G  p.Tyr1014Cys  IND  73.8  28.5  0.889  Damaging  Probably damaging  
L967S  c.2900T>C  p.Leu967Ser  VCC  74.4  24.7  0.659  Damaging  Possibly damaging  
Variants with function >75% WT-CFTR 
T1053I  c.3158C>T  p.Thr1053Ile  Non CF  78.8  26  0.899  Damaging  Possibly damaging  
F508C  c.1523T>G  p.Phe508Cys  Non CF  114.0 29.4  0.865  Damaging  Probably damaging  
I807M  c.2421A>G  p.Ile807Met  Non CF  115.2  21.9  0.738  Damaging  Probably damaging  
V562I  c.1684G>A  p.Val562Ile  Non CF  116.4  23.8  0.637  Damaging  Benign  
D836Y  c.2506G>T  p.Asp836Tyr  Non CF  122.1  32  0.924  Damaging  Probably damaging  
R170H  c.509G>A  p.Arg170His  Non CF  150.4  34  0.829  Damaging  Probably damaging  
CF = CF-causing; VCC = Varying Clinical Consequence; Non CF = Non CF-causing; IND = Indeterminate 
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Table 2.4 Predicted functional consequences of missense variants 
  CADD REVEL SIFT PolyPhen-2 
Functional grouping  n Del Not Del Del Not Del Dam Tol  Pr/Po Dam Ben 
<10% 21 21 - 19 2 17 4 19 2 
10% to <25% 9 9 - 8 1 7 2 8 1 
25% to 75% 12 11 1 8 4 8 4 8 4 
>75% 6 6 - 5 1 6 - 5 1 













Chapter 3. Residual Function of Cystic Fibrosis Mutants 




Treatment of individuals with cystic fibrosis (CF) has been transformed by 
modulator therapies that target select molecular mechanisms affecting function of the CF 
transmembrane conductance regulator (CFTR). However, allelic heterogeneity and low 
frequency of alleles present significant challenges to therapeutic classification of 
pathogenic variants. Approximately 1,650 variants have been identified in individuals 
with CF; most variants have been observed in fewer than 10 individuals worldwide and 
only 39 genotypes are FDA approved for CFTR modulator therapy. To generate data 
useful for expansion of treatment eligibility, we stably expressed 43 CFTR variants from 
a single integration site in the genome of CF Bronchial Epithelial (CFBE) cells and 
evaluated CFTR function by measuring transepithelial ion transport. We found that most 
variants demonstrated a modest elevation of CFTR function in response to all treatments 
tested. Importantly, we found that the magnitude of therapeutic response was highly 
correlated with residual CFTR function for the potentiator ivacaftor (r = 0.96), the 
corrector lumacaftor (r = 0.83), and the ivacaftor-lumacaftor combination (r = 0.93). 
Response of a partially overlapping set of 16 variants studied in a similar manner using 
Fisher Rat Thyroid (FRT) cells, a robust system for studying CFTR biology, showed 
nearly identical correlations. As expected, only a small subset of variants demonstrated 
statistically significantly greater response to specific treatments, presumably due to direct 
interaction between modulator action and molecular mechanism of disease. Furthermore, 
40/43 variants studied in CFBE cells and 13/16 variants studied in FRT cells 
demonstrated highest response to combination therapy. The variants studied here 
represent 87% of individuals in the CFTR2 database who carry at least one missense 
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variant, indicating that most individuals with CF caused by missense variants are likely to 
demonstrate modest response to currently available modulator therapy while a small 
fraction will show significantly elevated responses. Additionally, our results indicate that 
most individuals with missense variants should derive greatest benefit from combination 
therapy and we found no variant for which monotherapy was more effective than 
combination therapy. These findings provide a path to expanding modulator therapy to a 
significant number of individuals with CF who have rare genotypes that cannot be 
studied by clinical trials. 
Targeting specific mutant forms of defective CFTR with orally bioavailable 
modulators has revolutionized treatment of cystic fibrosis (CF) [3,93–95]. Ivacaftor, the 
first drug to achieve FDA approval, potentiates function by altering chloride channel 
gating and increasing the open probability (Po) of CFTR[29,96,97]. Ivacaftor was 
originally approved for individuals with CF who carried at least one copy of the 
p.Gly551Asp (G551D) variant. Subsequent clinical trials demonstrated benefit for 
individuals with CF who carried at least one copy of any one of eight variants that 
affected the gating of CFTR [18,98]. The second drug, lumacaftor, was developed to 
correct protein folding defects caused by the most common CF causing variant, 
p.Phe508del (F508del) [30,99]. While lumacaftor alone was not clinically effective for 
individuals homozygous for F508del [20] in subjects with cystic fibrosis homozygous for 
the F508del-CFTR mutation}, co-administration of lumacaftor and ivacaftor improved 
clinical outcome measures for individuals homozygous for F508del [21]. Recently, 
tezacaftor, a second corrector compound demonstrated clinical efficacy in F508del 
homozygotes when combined with ivacaftor [32]. The same combination of CFTR-
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targeted drugs also proved efficacious in a clinical trial of individuals with CF who 
carried F508del in trans with a select set of ‘residual’ function variants [24]. 
Ivacaftor alone or in combination with either lumacaftor or tezacaftor has 
demonstrated efficacy for 39 of the ~1640 CFTR variants associated with CF 
(http://www.CFTR2.org). This leaves thousands of individuals with CF who carry 
variants that have not been approved or in many cases even experimentally tested for 
response to these three drugs. Review of the untested variants indicates that 
approximately 50% are predicted to generate CFTR protein, and therefore could 
potentially be targeted with the currently available drugs [3]. Unfortunately, clinical trials 
of uncommon variants are difficult to conduct due to the wide geographic dispersion of 
the small number of individuals carrying these variants. Moreover, the high cost of CFTR 
modulators has made off-label prescription problematic. Even if an individual with a rare 
variant responds well in the clinic, insurers may not support the cost of treatment unless 
the modulator is FDA-approved for that particular genotype. Thus, alternative approaches 
are needed to assess the response to CFTR modulators for rare variants. Cell-based 
functional assays represent an avenue for evaluating rare variants in cases where clinical 
studies or assessment of primary tissues are impractical, provided these systems are well 
vetted and generate reproducible results. Fischer Rat Thyroid (FRT) cells have been 
extensively used as a model cell line for studying the role of CFTR in epithelial ion 
transport [100,101] and FRT cell lines expressing CFTR cDNA have been used in a 
number of studies to generate response data that have provided preliminary evidence to 
proceed to clinical trials [17,22,29,30], and more recently, to facilitate drug label 
expansion [102]. CF Bronchial Epithelial CFBE41o- (CFBE) cells provide an opportunity 
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to test the effects of CFTR variants in a human cell line from a relevant tissue type with a 
transcriptome that is very similar to that of primary airway epithelial cells [15]. These 
two cell lines offer complementary platforms to evaluate the functional consequences and 
responses to modulators of CFTR missense variants in a standardized and reproducible 
manner. 
In this study, we utilized CFBE cells stably expressing CFTR missense variants to 
extend our understanding of drug responses to CFTR bearing rare (minor allele frequency 
(MAF) <1% in the CF population) missense variants. Our initial goal was to identify 
variants with either positive or less favorable responses to ivacaftor, lumacaftor, or 
ivacaftor-lumacaftor combination treatment to inform clinical applications. However, we 
discovered that response to the modulators was closely correlated with residual function 
of the mutant forms of CFTR for most variants expressed in CFBE cells. This 
observation was replicated with a different set of missense variants expressed stably in 
FRT cells and was also apparent upon retrospective analysis of previously published 
ivacaftor studies using another independent set of FRT cells [22]. Using these results, we 
devised a statistically valid approach to identify robust responders to ivacaftor and 
lumacaftor based on the fold change in CFTR function. Furthermore, we showed that the 
combination of the two modulators produces a greater response for most missense 
variants, including high response variants, than either drug alone. These observations, in 
concert with the recent demonstration that combinatorial treatment was efficacious for 
residual function variants [24], suggest that CFTR-targeted treatment may be appropriate 
for most individuals with CF carrying residual function missense variants. 
3.2 Results 
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To assess the response of CFTR variants associated with a wide range of CF 
phenotypes to FDA approved CFTR modulators, we studied 57 missense variants 
reported in individuals with CF using two cellular expression systems. Forty-three rare 
missense variants that were associated with a range of phenotypes measured by modest 
increases in sweat chloride concentration (40-90 mM) and/or pancreatic exocrine 
sufficiency (PS) prevalence greater than 50%, were selected from the CFTR2 database 
(Table 3.1) and reported previously [8]. Due to the moderate pancreatic disease, each 
variant was expected to allow residual CFTR function [103,104] and was associated with 
less severe disease. To approximate the native environment of CFTR in the lung, the rare 
variants were studied in CF bronchial epithelial (CFBE41o-) cells that are devoid of 
endogenous CFTR expression [15,105]. These CFBE cells have been used to generate 
cell lines expressing CFTR missense variants at a level comparable to primary human 
tissues in order to measure their effect on CFTR function and aid in interpretation of 
disease liability [8]. A second set of 16 variants were expressed in FRT cells (Table 3.2), 
a cell type that has been employed to evaluate the response of CFTR to FDA approved 
drugs [102], although the studies presented here were performed on cell lines selected 
within a more narrow range of mRNA expression. These variants are generally more 
frequent in individuals with CF and are associated with more severe disease (60-106 mM 
and 2-80% PS). Two variants, p.Arg334Trp (R334W) and p.Thr338Ile (T338I), were 
common to both groups yielding a total study set of 57 unique variants. Variants F508del 
and G551D that have been extensively studied previously were also analyzed in both cell 
lines [3], bringing the total number of cell lines studied here to 63. 
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In each cell system, CFTR bearing each of the missense variants was stably 
expressed from a single site of integration, as previously described [8,15,22,106]. 
Residual CFTR function of each missense variant in CFBE cells was measured as the 
magnitude of forskolin-mediated (10 µM) cAMP-stimulated current inhibited by 
CFTRinh-172 (inh-172; 10 µM), a widely used potent inhibitor of CFTR [107], 
normalized to wild type (WT) function based on mRNA expression level as previously 
described [8] to calculate a precise %WT function. CFTR function in FRT cells was 
measured as the magnitude of forskolin-mediated (5 µM) cAMP-stimulated current (with 
specificity confirmed by inh-172 (10 µM)) compared to WT. All FRT cell lines selected 
for study expressed CFTR mRNA within a narrow range (0.5 – 1.5 fold) of CFTR mRNA 
compared to a WT-expressing line generated by the same method [106]. The four 
variants studied in both CFBE and FRT cells, (R334W, T338I, F508del, and G551D) 
produced comparable levels of CFTR function: F508del (CFBE, 0.5% WT; FRT, 1.6% 
WT); G551D (CFBE, 3.2% WT; FRT 4.0% WT); R334W (CFBE, 2.0% WT; FRT 3.9% 
WT); T338I (CFBE, 6.4% WT; FRT, 7.6% WT) (Table 3.1 and Table 3.2). 
CFTR missense variants expressed in CFBE cells were first tested for their 
response to 10 µM ivacaftor, a compound that is efficacious for variants that affect 
channel gating [29]. G551D-CFTR in CFBE cells demonstrated a dose dependent 
response to ivacaftor from 0.1 µM to 100 µM, similar to previously reported findings in 
FRT cells [29] (data not shown). Ivacaftor enhanced the forskolin (10 µM) -stimulated 
function of many of the variants tested in CFBE cells regardless of whether or not they 
were known to impair CFTR channel gating. Furthermore, the magnitude of ivacaftor 
enhanced CFTR activity correlated with the magnitude of forskolin activated CFTR 
 53 
activity (r = 0.96) (Figure 3.1A; Table 3.1; Supplemental Table 3.1). Data were plotted 
on logarithmic scale to visualize the entire functional range of variants studied. To 
determine whether the observed correlation between ivacaftor response and residual 
function was cell-line independent, we analyzed the ivacaftor response of 16 CFTR 
variants and the G551D and F508del variants stably expressed in FRT cells. The response 
to ivacaftor also correlated with forskolin activated CFTR function for all 18 variants 
expressed in FRT cells (r = 0.93) (Figure 3.1B; Table 3.2). 
When data from CFBE and FRT studies were combined and evaluated as fold 
change over baseline function, four cell lines (G551D expressed in both CFBE and FRT 
cells, p.Ser1159Phe (S1159F) and p.Ser1159Pro (S1159P) in CFBE cells) were found to 
be outliers (defined here as greater than 2SD above the mean of all variants tested) and 
labeled as ‘high response’. G551D is the prototype for highly-responsive gating variants 
[29,108] while S1159F and S1159P are two previously uncharacterized variants. When 
these outliers were removed, mean and SD were recalculated for all remaining data and 
four outliers from this analysis (p.Phe311Leu (F311L), p.Met348Val (M348V), 
p.Thr1246Ile (T1246I), and p.Asn1303Lys (N1303K)) were separated and labeled as 
‘intermediate response’; all other variants were labeled as ‘modest response’ variants, 
which accounted for the vast majority of variants (Figure 3.1C).  F311L, M348V, and 
T1246I are three previously untested variants while N1303K is a variant of particular 
interest. Single-channel studies revealed that once delivered to the plasma membrane, 
CFTR bearing N1303K exhibited a severe gating defect characterized by infrequent brief 
channel openings reminiscent of the G551D variant (Supplemental Figure 3.1A) 
[109,110]. Ivacaftor (1 µM) modestly enhanced open probability (Po) of the N1303K 
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variant by increasing the frequency and duration of channel openings (Supplemental 
Figure 3.1B-E). Taken together, the Isc and single-channel studies indicate that ivacaftor 
can elicit an increase in N1303K function although the extremely low residual function 
prevents a large absolute change CFTR function after ivacaftor treatment. 
We next evaluated previously published ivacaftor response data generated by 54 
CFTR variants stably expressed in a separate FRT cell line established by Vertex 
Pharmaceuticals (noted here as FRT*) that overlapped with the 16 variants expressed in 
FRT cells in this study [22]. Experimental conditions for measuring CFTR function were 
comparable to those used for the CFBE [15] and FRT [22] stable cell lines studied here. 
Correlation was evident for the variants studied in the FRT* cell lines (Figure 3.1D). 
Although drug doses differed between data sets, the CFBE and FRT data from this study 
were normalized to cells expressing WT-CFTR treated with the same drug doses, 
allowing for comparison across cell types. When high and intermediate response variants 
were removed from analysis, the regression functions for all 3 independent studies had 
very similar slopes, intercepts, and high correlation (Figure 3.1E). These results indicate 
that ivacaftor increases CFTR function for most variants regardless of the specific 
molecular defect as the variants studied confer a range of defects in CFTR function. 
Overall, the variants shared between studies yielded the same quality of ivacaftor 
response across systems, i.e. high response variants in one system were high response 
variants in other systems. The fold increase in current following ivacaftor treatment was 
similar in both cell lines for F508del (1.76 in CFBE and 1.31 in FRT), G551D (6.81 fold 
in CFBE and 6.02 fold in FRT), R334W (1.03 fold in CFBE and 1.24 fold in FRT), and 
T338I (2.21 fold in CFBE and 1.58 fold in FRT). 
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Identification of variants that allow CFTR to fold to a mature form but cause it to 
be poorly responsive to ivacaftor could be informative for future drug design and 
optimization. To screen for potential poor responders, we plotted the published folding 
and chloride channel function effects of 54 CFTR variants [17,22] (Figure 3.2A). We 
noted that a group of variants p.Ile336Lys (I336K), T338I, p.Ser341Pro (S341P), 
R334W, and p.Arg347Pro (R347P) located in transmembrane segment 6 (TM6) in 
membrane-spanning domain 1 (MSD1) of CFTR permitted partial folding, but severely 
disrupted channel function. TM6 is notable for its role in ion conductance [111] as it is 
predicted to line the channel pore by homology models and cryo-electron microscopy 
structures[112–117], measurements of conductance properties [118–120], and evaluation 
of solvent accessibility [121–124]. Based on these data, we hypothesized that variants 
which alter residues lining the channel pore might be resistant to CFTR potentiators, such 
as ivacaftor [17,22]. The nine naturally occurring TM6 variants generated detectable 
mature (band C) CFTR which suggested that each variant may allow at least partial 
CFTR maturation and residual CFTR function (Figure 3.2B). Furthermore, the ivacaftor 
response of TM6 variants increased as residual function increased from <1% WT to 78% 
WT, indicating that the two measurements are correlated (Figure 3.2C). The responses of 
the TM6 variants to ivacaftor were modest and not different from the total set of modest 
response variants (Figure 3.2D). Furthermore, 2 TM6 variants, p.Arg334Gln (R334Q) 
and T338I, responded very similarly to a separate collection of 10 CFTR potentiator 
compounds obtained from CF Foundation Therapeutics (CFFT) CFTR Chemical 
Compound Program (Supplemental Figure 3.2). Although TM6 variants had minimal 
residual CFTR function despite some of them having efficient protein folding, a 
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characteristic shared with ‘gating’ variants, they are distinct in that generated a modest 
response to potentiators which was correlated with residual function similar to non-gating 
missense variants. 
Our next step was to test the response of the missense variants to the CFTR 
corrector lumacaftor. Lumacaftor improves the biogenesis of CFTR protein and has been 
primarily targeted to the common misfolding variant F508del [30]. Importantly, 
lumacaftor has been reported to increase the function of WT CFTR and a few missense 
variants [33,34] and protein folding of several other variants [125,126]. Accordingly, we 
tested the effect of lumacaftor on the variants studied here. As with ivacaftor, the 
magnitude of forskolin stimulated CFTR function following incubation with 6 µM 
lumacaftor correlated with the forskolin stimulated function of each variant when 
incubated with an equal volume of DMSO for the 45 variants studied in CFBE cells 
(Figure 3.3A, Table 3.1). Correlation between residual function and lumacaftor response 
was also observed in 18 variants expressed in FRT cell lines (Figure 3.3B, Table 3.2). 
Like the ivacaftor response, data from CFBE and FRT cells were combined and evaluated 
as fold response. Outliers for the lumacaftor response were determined by measuring 
2SD above the mean; p.Gly91Arg (G91R), p.Glu92Lys (E92K), p.Leu138insLeu 
(L138ins), p.Leu145His (L145H), and p.Leu206Trp (L206W) were designated as high 
response variants, while p.Gly27Arg (G27R), p.Pro67Leu (P67L), p.Ile340Asn (I340N), 
and p.Tyr1032Cys (Y1032C) were designated as intermediate response variants (Figure 
3.3C). When high and intermediate response variants were removed from the analysis, 
the regression functions for CFBE and FRT modest response variants demonstrated 
robust correlation (CFBE r = 0.95, FRT r = 0.98) with similar slopes (Figure 3.3D). 
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These results indicate that lumacaftor increases CFTR function for most variants 
regardless of the specific molecular defect as the 59 variants studied confer a range of 
folding defects in CFTR from mild to severe. 
Lumacaftor has been shown to be effective at improving the protein processing of 
variants located in MSD1 [125] and the intracellular loops [126]. We were intrigued that 
two variants (I336K and I340N) located in TM6 within MSD1 demonstrated elevated 
responses to lumacaftor, which prompted further studies to verify and explain the 
responses of these two TM6 variants. Lumacaftor increased the total amount of mature 
CFTR protein expressed in stable CFBE cell lines for all variants (Figure 3.4A), even 
though many of them are naturally fully folded and processed (note absence of immature 
band B protein for most variants). We confirmed that this increase in protein quantity was 
not due to an increase in CFTR mRNA (Supplemental Figure 3.3). Given the variability 
in the fold response to lumacaftor (see Figure 3.3A, 3.3B), we tested up to 4 
independently derived CFBE cell lines stably expressing each of the nine TM6 variants 
(Figure 3.4B). Multiple measurements of the different clones of TM6 variants 
demonstrated that the response to lumacaftor becomes more pronounced at higher levels 
of residual function (Figure 3.4C). Notably, two TM6 variants (I336K and I340N) had 
significantly higher fold responses than the remaining 7 TM6 variants (Figure 3.4D). To 
explore whether the less responsive TM6 variants respond to other CFTR correctors, we 
evaluated R334Q and T338I alongside the highly responsive variant I340N using a series 
of 18 compounds obtained from the CFFT CFTR Chemical Compound Program. Only 
two compounds generated a greater response compared to the vehicle control (DMSO) 
for all 4 variants tested (C17 and C18), but neither approached the efficacy of lumacaftor 
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(Supplemental Figure 3.4). Since the TM6 variants are located on an alpha helix that 
spans the cell membrane, we speculated that the robust corrector activity might be related 
to the orientation of the side chains of the mutated residues relative to the proposed ion 
pore. Using the predicted alpha helical structure of TM6 when CFTR is in its open 
conformation, the side chains of residues R334, T338, S341, and M348 are predicted to 
reside in the channel pore, while I336, I340, and A349 are oriented such that they are 
embedded in either the protein or the lipid bilayer (Figure 3.4E). The results of arginine 
scanning mutagenesis are consistent with this orientation for these residues [127] as are 
the cryo-EM structures of CFTR in the ATP-bound state [117]. Grouping of the 
responses of TM6 variants by predicted orientation revealed a significant correlation with 
lumacaftor response (Figure 3.4F). These results suggest that amino acid substitutions at 
embedded residues in TM6 are particularly responsive to lumacaftor. 
The combination therapy of ivacaftor and lumacaftor (iva/lum) and ivacaftor 
paired with a different corrector, tezacaftor, has demonstrated clinical benefit in 
individuals homozygous for F508del [21,32], and the latter combination is effective for 
individuals carrying one copy of F508del and a variant that allows partial CFTR function 
[24]. Based on these observations and the responses we observed with potentiator and 
corrector alone, we sought to determine the effects of acute administration of ivacaftor 
after incubation (24 h in CFBE cells or 48 h in FRT cells) with lumacaftor (iva/lum) on 
the 59 variants tested here. The response of 45 variants stably expressed in CFBE cells to 
iva/lum correlated with CFTR function without modulators (Figure 3.5A). Results 
obtained from 18 variants expressed in FRT cells demonstrated a similar relationship 
(Figure 3.5B). High response and intermediate response variants were separated from 
 59 
modest response variants (Figure 3.5C); G91R, E92K, L138ins, L145H, and G551D 
(CFBE) were designated high response variants, while L206W, I336K, G551D, and 
N1303K were designated as intermediate response variants (note absolute magnitude of 
N1303K activity is quite low, although the relative modulator enhancement is 
substantial). Trend lines of modest response variants were again found to be very similar 
between CFBE and FRT cell lines (Figure 3.5D). Plotting of all variants studied revealed 
robust correlation between forskolin stimulated CFTR function and iva/lum enhanced 
CFTR function illustrating that this relationship is independent of cell type and 
pathologic mechanism for each variant (Figure 3.5D). 
To formally test whether the combination of ivacaftor and lumacaftor produces 
higher responses than either compound alone, we performed detailed analysis of the 45 
variants expressed in CFBE cells. Iva/lum combination treatment generated an equal or 
better response than either ivacaftor or lumacaftor for 30 out of 33 variants that 
demonstrated modest responses to both ivacaftor and lumacaftor (Figure 3.6A). The 
variants which did not demonstrate significantly better function with the iva/lum 
combination were p.His139Arg (H139R), R334W, and p.Asp513Gly (D513G) and these 
variants also did not demonstrate a significant response to either ivacaftor or lumacaftor. 
Five rare variants were found to have an intermediate or high response to ivacaftor; for 
these five variants iva/lum combination treatment was greater or equal to either ivacaftor 
or lumacaftor treatment (Figure 3.6B). Six variants were intermediate or high response 
variants to lumacaftor treatment; for these six variants iva/lum combination treatment 
was greater or equal to either ivacaftor or lumacaftor treatment (Figure 3.6C). Notably, 
the iva/lum combination was never worse than ivacaftor or lumacaftor alone. Out of the 
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45 rare variants evaluated, the response was not statistically significantly higher than 
forskolin stimulated function only for H139R, R334W, and D513G. 
Although the trends for modest response variants are the results that apply to the 
majority of variants and individuals with CF, the responses of the intermediate and high 
response variants also warrant evaluation. We compared the regression lines for modest, 
intermediate, and high response variants for ivacaftor, lumacaftor, and iva/lum 
combination (Figure 3.7A). This analysis demonstrated that each response group yielded 
a steeper slope of the regression for all three treatments. These steeper slopes suggest that 
higher response variants were distinguished by more effective modulator responses and 
were not the simple top end of a normal distribution; we believe that the regressions 
would be parallel but elevated if the latter were the case. When we compared across each 
tier of response, modest, intermediate, and high, we found that the iva/lum combination 
generated the steepest regression for all three response levels (Figure 3.7B). Taken 
together, these results suggest that high response variants are mechanistically distinct 
from modest response variants and that iva/lum combination therapy is the best option for 
all variants regardless of whether they are a modest or high response variant. 
3.3 Discussion 
The CFTR modulators ivacaftor and lumacaftor have been approved for treatment 
of individuals with CF who carry a select set of variants based on the specific 
mechanistic defects of those variants. However, clinical studies of individuals with 
variants for which aberrant channel gating or folding is not the sole molecular defect, 
such as p.Pro67Leu (P67L) [128], p.Arg117His (R117H) [98], and other residual 
function variants [24,129], have all shown clinical benefit from ivacaftor in a mechanism 
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independent manner. Using a wide range of variants expressed in two cell types, we show 
that residual CFTR function and drug response are highly correlated. Furthermore, we 
demonstrate that almost all tested variants generate higher currents in response to 
ivacaftor combined with lumacaftor than when treated with either compound alone. 
Following the common CF-causing variant F508del [130], missense variants represent 
the largest category of remaining variants associated with CF [3]. Although the number 
of missense variants studied here encompass a small fraction of all missense variants 
reported in CFTR (57 out of >800), they represent a significant portion of CF causing 
alleles in the CF population. In total, the missense variants evaluated by this study here 
represent 10% of all alleles reported to CFTR2 and 13,062 out of 15,082 individuals 
(87%) with at least one missense variant. Of added significance to the CF community 
moving forward, our results predict that greater clinical benefit would likely be derived 
from combinatorial therapy for most individuals with CF who carry missense variants 
and are given modulator compounds. The utility of this approach was recently 
demonstrated by a clinical trial employing modulator combinations (ivacaftor and 
tezacaftor) for individuals with residual CFTR function [24]. 
Heterologous expression of CFTR mutants in FRT cells has been used extensively 
to test modulator response, particularly to ivacaftor [17,22,29,30,125]. Based on the 
clinical efficacy and safety of ivacaftor, the FDA elected to accept results of CFTR 
testing in FRT cells as evidence to allow expansion of ivacaftor use without requiring 
clinical trials [102]. This decision was reached based on the strong correlation between in 
vitro studies using FRT cells and clinical trials. Importantly, the results of those studies 
agreed despite using a non-human cell line expressing a single allele of CFTR. This 
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forwarding thinking approach provides a path to treat every individual with CF who 
carries CFTR variants that are sufficiently responsive to modulators and provides a 
mechanism to address barriers of formal clinical testing for CF individuals with ultra-rare 
or even private mutations. However, the possibility remains that certain variants or 
certain modulators will require CFTR to function in its native human airway cellular 
context. To this end, we tested variants in CFBE cells and compared our results to the 
FRT model that has been well established as a system for studying CFTR modulators. 
The CFBE and FRT cell lines used here expressed CFTR in a controlled manner by stable 
expression from a single locus which guarded against artefactual interpretation of 
variants due to overexpression of the allele. For example, the finding of N1303K 
response to ivacaftor, if taken on its own, could be suggestive of clinical benefit, but the 
function in the expression controlled FRT cell line demonstrates that the response is quite 
low and less likely to reach levels sufficient for clinical benefit. mRNA levels of CFTR 
expressed in CFBE cells were also determined to be within normal physiological limits of 
native human tissues by RNAseq studies. Despite their differences, we believe that our 
efforts to maintain controlled expression allowed CFBE and FRT cells to generate highly 
consistent results across a wide range of variants. The slopes and intercepts of correlation 
between residual function and modulator responses were remarkably similar, suggesting 
that the observed relationships were highly likely to be due to CFTR rather than cell-
specific factors. 
Ivacaftor increased chloride currents of G551D-CFTR by almost 7-fold in both 
cell lines, which is significantly less than was observed in previous studies in FRT cells 
[17,22], but more consistent with studies performed in primary cells [29] and other 
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cellular contexts [96,97]. The rare variants S1159F and S1159P, located prior to the 
second nucleotide-binding domain (NBD2) [131], also exhibited a high response to 
ivacaftor. Even after removing high response variants from the analysis, a second set of 
variants demonstrated a response to ivacaftor that was significantly elevated compared to 
the remaining variants. The high degree of correlation between residual function and 
modulator response for modest response variants (r = 0.94) suggests that baseline 
function might predict ivacaftor response for all variants and not just the ones tested here. 
Although absolute response to modulators may not be sufficient for very low function 
variants to demonstrate significant clinical benefit, i.e. crossing a 10% WT function 
disease threshold, evaluation by fold change could inform mechanism of action. Such 
mechanisms may be distinct from potentiator compounds that promote NBD dimerization 
[132], and guide rationale design of more effective potentiators. In addition, 
differentiating variants that have exceptional responses will be important to establish 
accurate expectations for clinical outcomes. 
The effect of lumacaftor on CFTR bearing missense variants has been less 
extensively studied than for ivacaftor, and the present study reports the largest collection 
of variants tested for their response to lumacaftor. Lumacaftor was designed to target the 
common F508del variant, and we observe increased CFTR function in cell lines 
expressing F508del when treated with this compound. Although we were unable to fully 
recapitulate the magnitude of effect previously published [30], we believe our findings of 
a 4 fold increase in function from 0.5% to 2% WT function are concordant with results 
from clinical studies demonstrating the ability of lumacaftor to reduce sweat chloride in a 
dose dependent manner up to a reduction of 6.6 mmol/l while being unable to 
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significantly improve lung function [20] as well as improving of biomarkers of CFTR 
function [133]. Correlation between residual CFTR function and lumacaftor response had 
previously been observed in studies of primary nasal epithelial cells bearing a small 
series of missense variants [51]. Furthermore, in vitro and ex vivo studies of missense 
variants demonstrate increased CFTR function following treatment with lumacaftor 
[33,134]. Thus, it is reasonable to expect that the observations in the CFBE and FRT cell 
lines will be relevant in vivo. We also identified missense variants which respond 
significantly better to lumacaftor than F508del (i.e. greater than 2SD above the mean). 
These results suggest that individuals carrying certain variants might respond better to 
lumacaftor than those who carry F508del. Although intermediate and high lumacaftor 
responses applied only to 9 variants, lumacaftor increased the CFTR function of most 
variants tested, regardless of the mechanism underlying their CFTR dysfunction. Thus, 
many individuals with CF who carry variants that allow protein production may also 
benefit from lumacaftor treatment. Given that tezacaftor is functionally similar to 
lumacaftor [135], we predict that the same benefit would be obtained when using this 
CFTR corrector, similar to what has been observed in studies of primary cells [51]. 
The location of the residues that confer high lumacaftor responses could inform 
the future development of correctors. Of the six variants that demonstrated robust 
responses to lumacaftor, four are located in the TMDs (E92K, L206W, I336K, and 
I340N), while the two variants with the highest responses are located in the intracellular 
loops (ICLs): L138ins and L145H near the first intracellular loop (ICL1) and Y1032C 
near the interface of TM10 and ICL4. Recent evidence indicates that lumacaftor 
promotes interactions between ICL1 and NBD1 [136] as well as between ICL4 and 
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NBD1 [126]. Thus, the significant increases in current above baseline exhibited by CFTR 
bearing L138ins and L145H upon treatment with lumacaftor might be a consequence of 
their locations. As lumacaftor is thought to rescue CFTR function by improving protein 
folding and hence, structure, we mapped the location of all TM6 variants studied here 
onto models [112] and structures [116] of the CFTR protein. I336K and I340N are found 
in TM6 at residues where cryo-EM structures [116,117], homology modeling [112], and 
experimental evidence predicts that they are embedded [122,123,127], whereas all other 
variants, except for p.Ala349Val (A349V), are predicted to be oriented into the open 
channel pore. Although the lumacaftor response of A349V was not found to be 
significantly different from all other missense variants, it was significantly higher than 
other TM6 variants (p<0.05). These results indicate that missense variants that alter ion 
conductance by disruption of the structure of the pore are mechanistically distinct from 
those which more directly impede ion flow. Amelioration of local folding defects 
imposed on the channel pore by variants such as I336K and I340N might underlie the 
prominent response of these variants to lumacaftor. 
Our extensive evaluation of responses of variants expressed in CFBE cells 
confirmed that the majority of variants (42/45) demonstrated increased CFTR function 
when treated with the combination of ivacaftor and lumacaftor. Moreover, 26 of 45 
variants demonstrated greater responses to the combination than to ivacaftor or 
lumacaftor alone, while 16 others showed an equal response to ivacaftor or lumacaftor 
that was higher than baseline function, and the combination was not found to be less 
effective than either individual modulator for any variant tested. Although some studies 
have observed antagonism between ivacaftor and lumacaftor for some genotypes 
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[134,137], we saw no evidence of antagonistic effects between these compounds in either 
CFBE or FRT systems. The regression functions suggest that a minimum (~2% WT) 
amount of residual function is required for ivacaftor action, likely due to the requirement 
of well folded and processed protein localized to the cell surface, while lumacaftor has no 
such requirement. The regression function for iva/lum combination treatment removes 
the minimum function requirement for response, suggesting that lumacaftor action results 
in ivacaftor response. It is known that F508del results in multiple molecular defects that 
require correction [138,139] and so combination therapy should therefore be expected to 
be the most effective treatment for F508del [140] and other variants that have folding and 
activity defects. Combination therapy was also effective for variants with high responses 
to ivacaftor or lumacaftor, including G551D, indicating that individuals bearing these 
variants could additionally benefit from combinatorial therapy. 
Of significant note, the modest response variants treated with the iva/lum 
combination crossed 10% WT function for variants with 3% baseline function. The 
threshold of 3% residual WT function as a differentiator of predicted alleviation of lung 
disease for combinatorial modulator therapy is important as this level of CFTR activity 
also coincides with an approximate threshold for exocrine pancreatic sufficiency [141]. 
Pancreatic sufficiency of an individual with CF can be determined independent of genetic 
testing, thus potentially removing hurdles to interpretation of genetic variants including 
incomplete genotyping, variants of uncertain significance, errors in genetic test reports, 
and extreme rarity of missense variants, among other considerations. Given the high 
correlation between baseline function and modulator response for modest response 
variants (r = 0.94), residual function of an individual may be a reasonable predictor of 
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drug response, which has been postulated previously based on studies of primary cells of 
a limited number of genotypes [51]. 
The exceptions to the modest responses to ivacaftor and lumacaftor are significant 
for individuals carrying those variants as well as for informing mechanism and design of 
future CFTR modulators. Individuals who carry these highly responsive variants may be 
able to achieve significant levels of CFTR function and improved clinical outcomes even 
if their CFTR function without treatment is poor. Secondly, understanding the 
mechanism underlying the strong response may inform development of more efficient 
versions of these modulators which can then confer larger responses to individuals 
carrying modest response variants as well. While these high response variants might lead 
to significant improvements in clinical outcome, it is important to note different tiers of 
response when discussing therapeutic outcomes with patients. The specific level of 
function required to escape lung disease will vary to some degree among individuals due 
to modifier genes, environmental factors, and/or stochastic factors unique to each 
individual, as noted in studies of twins and siblings [142]. The level of CFTR function 
required to demonstrate clinical benefit which may in some cases be as low as 5%, as 
implied by RNA studies [44] or possibly as high as 25%, which was necessary to restore 
full ciliary function [47]. Of note, the conservative threshold of 10% WT function is 
higher than what was achieved for combinatorial treatment of F508del in both FRT and 
CFBE systems. This is important, since the combination of ivacaftor and lumacaftor has 
achieved clinical benefit and FDA approval for individuals who carry two copies of 
F508del [21].  If the response of mutant CFTR to newer derivatives and novel classes of 
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modulators continues to correlate with residual function, it is possible that therapeutic 
response might be achieved in individuals with very minimal residual function. 
3.4 Materials and Methods 
Study design 
Rare missense variants from the CFTR2 database which had moderate sweat 
chloride (40-90 mM) were selected for study in CFBE cells. The set of moderate sweat 
variants were ranked in priority based on frequency within the CF population. Variants 
which had <10% WT function were selected to evaluate drug responses. Additionally, 
several of the first cell lines made were also tested for drug response even if their residual 
function was greater than 10% WT (D979V, Y1032C, G622D, P5L). Missense variants 
from TM6 were based on previous studies [22,111] (R334W, I336K, T338I, and S341P) 
or naturally occurring variants at positions of interest (R334L, R334Q, I340N, M348V, 
A349V). All TM6 variants were tested for drug response regardless of residual function. 
In total, variants were selected across a range of clinical and molecular phenotypes to 
identify trends which might be useful for predicting the drug response of novel missense 
variants identified in individuals without the need for in vitro testing. Functional testing 
was measured with a minimum of n = 3 for each cell line tested for each drug condition 
as well as a minimum of n = 3 for measurement of CFTR expression by qRT-PCR. Drug 
doses were assigned based on previous studies [15,17,22,29,30] and compared to 
equivalent treatment with the drug vehicle (DMSO in all cases). 
Generation of variant plasmids 
A pEF/FRT expression plasmid (Life Technologies) containing WT-CFTR cDNA 
sequence was used as a template for generation of variant alleles of CFTR by site directed 
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mutagenesis. Mutagenesis was confirmed by sequencing of the complete CFTR cDNA 
sequence to guard against secondary mutations. Plasmids were confirmed to be 
competent for transfection by transient transfection of HEK293 cells and subsequent 
Western blotting to evaluate production of protein as well as the effect of each variant on 
CFTR processing. 
Generation of stable cell lines 
A CFBE derived cell line containing an FLP-recombinase recognition target 
(FRT) integration site [15] were transfected with CFTR variant plasmids in the presence 
of the pOG44 recombinase plasmid. Cells were grown under hygromycin selection and 
individual clones were picked using cloning cylinders and grown/expanded separately. 
Isogenic Fisher Rat thyroid (FRT) cells (a generous gift from Dr. M. Welsh, University 
of Iowa) encoding CFTR variants were generated using the Flp-In™ system (Thermo) 
following previously published methods [22,106]. CFTR cDNAs encoding variants were 
cloned between NotI and XhoI restriction sites of the pcDNA5/FRT expression vector. 
All variants encoded the common polymorphism methionine at position 470 except three 
(G85E, R347P, and M1101K), which were instead generated with valine at this position 
to reflect haplotypes commonly associated with these complex alleles. Multiple clones of 
FRT cells expressing each variant were isolated and CFTR mRNA levels compared to an 
established wild-type CFTR line obtained by the same protocol. Only cells with mRNA 
levels comparable to wild-type (within 0.5-1.5 fold) as determined by quantitative RT-
PCR were selected for further study. 
Confirmation of CFTR expression 
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Integration of CFTR variant plasmids was evaluated by extraction of genomic 
DNA from hygromycin resistant cell lines and PCR amplification of the entire CFTR 
cDNA as well as of an empty FRT integration site. Cell lines that contained the entire 
CFTR cDNA and had an interrupted FRT site were expanded for further testing, all other 
cell lines were discarded. To confirm expression from the integrated plasmid, cells were 
plated to confluency and grown for 6 days. Total RNA was extracted and 500 ng was 
used for generation of a first strand cDNA library. qRT-PCR was performed using 2 
primer sets within the CFTR cDNA sequence as well as internal primers for the 
housekeeping gene HPRT1; B2M, GUSB, GAPDH, and TBP were also evaluated as 
housekeeping genes, but HPRT1 was determined to have the most stable expression 
under our test conditions. Cells were discarded if they failed to demonstrate measurable 
CFTR expression, lower limit of detection was approximately 7 cycles higher than 
HPRT1. 
Measurement of CFTR function in epithelia 
CFBE analysis 
CFTR-mediated transepithelial Cl- currents were recorded using a large Cl- 
concentration gradient to magnify current size without permeabilizing the basolateral 
membrane as previously described [15,33]. To test the function of CFBE cell lines, two 
aliquots of cells were plated to confluency, one was used to determine function by short 
circuit current (Isc) measurements and the other was used to measure mRNA at the time 
of Isc measurements. CFBE cells (1x105) were plated on Snapwell filters (Corning) and 
cultured while submerged to a minimum transepithelial resistance (Rt) of 200 Ω•cm2 
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while cells for RNA extraction were plated in flat bottom 6 well plates. Cells were grown 
in DMEM with 10% FBS without hygromycin and media was changed daily for 6 days. 
Isc measurements were performed with EasyMount Ussing chambers (Physiologic 
Instruments, CA) using a chloride concentration gradient with high chloride buffer in the 
basolateral chamber and low chloride buffer in the apical chamber. The apical buffer 
contained 145 mM NaGluconate, 1.2 mM MgCl2, 1.2 mM CaCl2, 10 mM dextrose, 10 
mM HEPES, and the basolateral buffer was composed of 145 mM NaCl, 1.2 mM MgCl2, 
1.2 mM CaCl2, 10 mM dextrose, 10 mM HEPES. Buffers were pH adjusted to 7.3 using 
NaOH and warmed to 37 °C prior to use. Air was gently bubbled into the buffers to 
promote circulation. After cancelling voltage offsets, transepithelial voltage was clamped 
(referenced to the basolateral solution) at 0 mV and Isc recorded continuously. Once 
currents had stabilized (10-30 min after mounting filters in Ussing chambers), forskolin 
(Selleckchem) was administered to the basolateral chamber at a final concentration of 10 
µM. Once stabilized at the maximal forskolin-stimulated current level, the inhibitor 
CFTRinh-172 (Inh-172, Selleckchem) was administered to the apical chamber at a final 
concentration of 10 µM. The contribution of CFTR function to overall current was 
measured as the decline in current following administration of Inh-172 (∆Isc). 
Assessment of the functional consequence of CFTR missense variants was performed by 
normalizing the ∆Isc based on mRNA quantity to generate a % of WT function value as 
described previously.  Briefly, the slope derived from the correlation between mRNA 
level (x) and short circuit current (Isc) in µA/cm2 (y) for 24 cell lines expressing WT-
CFTR is expressed as y=242.61(x) [8]. This is the slope for 100% function. The CFTR 
mRNA level of each variant (mRNAvar) is determined by normalizing against the mRNA 
 72 
level of the housekeeping gene HPRT1 which are each expressed at similar levels in all 
cell lines.  Using the Isc generated by each variant (Isc-var), the % CFTR function of a 
variant relative to WT-CFTR (Fvar) is calculated as follows: 
Fvar=100% X (Isc-var/242.61 (mRNAvar))  Eq. 1 
FRT analysis 
FRT cells (1.5x105) were seeded and cultured on Transwell permeable supports 
(Corning) for 5 days to form well polarized monolayers with a minimum transepithelial 
resistance (Rt) of 400 Ω•cm2. Isc was evaluated in the presence of basolateral to apical 
chloride concentration gradient with an EasyMount Ussing Chamber System 
(Physiologic Instruments, CA) and Acquire and Analyze software. Briefly, transwell 
inserts were mounted into chambers bathed in low chloride Ringer`s solution (1.2 mM 
NaCl, 140 mM Na-gluconate, 25 mM NaHCO3, 3.33 mM KH2PO4, 0.83 mM K2HPO4, 
1.2mM CaCl2, 1.2 mM MgCl2, 10 mM glucose) bathing the apical surface and 
physiological Ringer’s solution (120 mM NaCl, 25 mM NaHCO3, 3.33 mM KH2PO4, 
0.83 mM K2HPO4, 1.2 mM CaCl2, 1.2 mM MgCl2, 10 mM glucose) bathing the 
basolateral surface. Once current had stabilized, 100 µM amiloride was applied to both 
the apical and basolateral sides of FRT epithelia to inhibit ENaC (epithelial sodium 
channel). To activate CFTR specific chloride current, 5 µM forskolin (Sigma) was added 
to both sides, followed by 5 µM ivacaftor (Selleckchem), to the apical side only. Finally, 
10 µM CFTRinh-172 (Sigma) was applied to the apical side to inhibit CFTR-mediated 
current. The process for determining %WT function in FRT cells was similar to that 
previously reported [5] but a much narrower range of mRNA expression was used. 
Briefly, cell lines were selected that had a very similar level of mRNA expression as cells 
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lines expressing WT-CFTR (0.5 – 1.5 fold) so that %WT function of the variant was 
derived after dividing the current generated in the cell line expressing the variant by the 
current generated by the cell line expressing WT CFTR. 
Western blotting 
Biochemical effects of small molecules on the expression of CFTR protein were 
evaluated by Western blot analysis [15,33]. For Western blots of transiently transfected 
CFTR expression plasmids, we used 40 µg of total lysate collected from HEK293 cells 
48 hours post transfection. CFTR was detected using the mouse anti-CFTR monoclonal 
antibody (596), which recognizes NBD2 of human CFTR [143]. Blots were probed with 
596 at a concentration of 1:5,000 and secondary anti-mouse antibody at a concentration 
of 1:100,000. 
For Western blots of stably transfected CFTR expression plasmids, we used 100 
µg of total lysate collected from CFBE cells. Blots were probed with 596 at a 
concentration of 1:1,000 and secondary anti-mouse antibody at a concentration of 
1:100,000. The sodium potassium (Na+/K+) ATPase (Abcam) was used as a loading 
control for all blots; primary antibody concentration was 1:50,000 and secondary 
antibody concentration was 1:200,000. All blots were imaged using ECL reagent (GE) 
and x-ray film. 
Potentiator testing 
CFBE cells were prepared for Isc measurements as described above (Measurement 
of CFTR function in epithelia). Following stabilization of the forskolin-stimulated 
current, ivacaftor (Selleckchem) was administered to the apical chamber at a final 
concentration of 10 µM. Potentiators from the CFFT CFTR Chemical Compound 
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Program were also administered into the apical chambers at concentrations corresponding 
to their published EC50 values [144–148]. Inh-172 was applied to measure the CFTR 
portion of the current. The effects of potentiators were measured as the Inh-172 inhibited 
portion (∆Isc) of the current when stimulated by forskolin and then enhanced by the 
potentiator compared to the  ∆Isc when stimulated by forskolin only. 
FRT cells were prepared for Isc measurements as described above, 5 µM forskolin 
(Sigma) was added to both sides, followed by 5 µM ivacaftor (Selleckchem), to the apical 
side only. Finally, 10 µM CFTRinh-172 (Sigma) was applied to the apical side to inhibit 
CFTR-mediated current. Ivacaftor enhanced function was measured as the ∆Isc of 
ivacaftor enhanced forskolin activated current and compared to ∆Isc when stimulated by 
forskolin only. 
Corrector testing 
CFBE cells were grown in the presence of corrector compound or equivalent 
volume of DMSO for 24 h prior to measurements. Lumacaftor (Selleckchem) was 
administered at a final concentration of 6 µM while corrector compounds obtained from 
the CFFT CFTR Chemical Compound Program were tested at concentrations 
corresponding to their EC50 values [149–154]. The effects of correctors on CFTR 
function were evaluated by Isc comparison of forskolin-stimulated CFTR currents of cells 
treated with each compound compared to the DMSO treated negative control. To 
evaluate the effect of lumacaftor on protein processing, total protein lysates were 
collected from stable cells after 24 h incubation with 3 µM lumacaftor or an equivalent 
volume of DMSO and Western blots were performed as described above (Western 
blotting). FRT cells were prepared for Isc measurements as described above. Forty-eight 
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hours prior to assay, cells were treated with 3 µM lumacaftor (Selleckchem) or vehicle 
(DMSO) from both apical and basolateral surfaces of the epithelia. The effects of 
correctors on CFTR function were evaluated by Isc comparison of forskolin-stimulated 
CFTR currents of cells treated with each compound compared to the DMSO treated 
negative control. 
CFTR single-channel studies 
CFTR Cl- channels were recorded in excised inside-out membrane patches from 
CHO cells co-expressing CFTR and GFP voltage-clamped at –50 mV as described 
previously [155]. Prior to experiments, the plasma membrane expression of N1303K-
CFTR was rescued by incubating transfected CHO cells at 27 °C for 3 – 7 days. The 
pipette (extracellular) solution contained (mM): 140 N-methyl-D-glucamine (NMDG), 
140 aspartic acid, 5 CaCl2, 2 MgSO4 and 10 N-tris[hydroxymethyl]methyl-2-
aminoethanesulfonic acid (TES) adjusted to pH 7.3 with Tris ([Cl-], 10 mM). The bath 
(intracellular) solution contained (mM): 140 NMDG, 3 MgCl2, 1 CsEGTA and 10 TES, 
adjusted to pH 7.3 with HCl ([Cl-], 147 mM; free [Ca2+], < 10-8 M) and was maintained at 
37 °C. 
CFTR Cl- channels were activated promptly following membrane patch excision 
using the catalytic subunit of protein kinase A (PKA [purified from bovine heart] 75 nM; 
Calbiochem) and ATP (1 mM; Sigma-Aldrich). To minimize channel rundown, PKA and 
ATP were added to all intracellular solutions. Because of the difficulty removing 
ivacaftor from the recording chamber [156] specific interventions with the drug were 
compared with pre-intervention controls. In this study, membrane patches contained ≤ 5 
active channels determined using the maximum number of simultaneous channel 
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openings observing the precautions described previously  to minimize errors counting 
channels. 
After recording, filtering and digitizing data, single-channel current amplitude (i), 
Po, mean burst duration (MBD) and interburst interval (IBI) were determined as 
described previously [109,155]. For wild-type CFTR, we used only membrane patches 
with a single active CFTR Cl- channel for burst analyses, whereas for N1303K-CFTR, we 
used only bursts of single-channel openings with no superimposed openings from 
membrane patches with ≤ 4 active channels [157]. 
Structural analysis 
Cryo-EM structures and homology models of the open conformation of CFTR 
[112,116,117] were used to map the position and orientation of the residues studied here 
using Pymol software and publicly available PDB files (5W81,5UAK, 2ONJ, 2HYD). 
Statistics 
Designation of modulator response outliers was performed by designating those 
responses with fold changes greater than 2SD above the mean as “high response”. High 
response variants were removed from the data set and outliers from the remaining dataset 
(greater than 2SD above the mean) were designated as “intermediate response” variants; 
all other responses were designated as “modest response”. Results are presented as mean 
values ± SEM for bar plots. Box plots divide the data by quartile with the median value 
indicated by a horizontal line within the box and whiskers extend to minimum and 
maximum values. Correlations were calculated by Pearson linear correlations. Statistical 
significance was calculated by Student’s unpaired two tailed t-tests. Differences were 
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considered statistically significant when p < 0.05. Complete individual data sets for each 
cell line are available in Supplemental Table 3.1. 
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Figure 3.1. Ivacaftor response correlates with residual function.  
(A) Ivacaftor (10 µM) enhanced CFTR function compared to residual forskolin (10 µM) 
stimulated CFTR function for 45 variants expressed in CF Bronchial Epithelial (CFBE) 
cells. Each variant measured n ≥ 3 and plotted as mean ± SEM. (B) Ivacaftor (5 µM) 
enhanced CFTR function compared to residual forskolin (5 µM) stimulated CFTR 
function for 18 variants expressed in Fisher Rat Thyroid (FRT) cells. Each variant 
measured n ≥ 3 and plotted as mean ± SEM. (C) Separation of variants based on their 
fold response to ivacaftor. Response of cell lines expressing G551D (CFBE), G551D 
(FRT), S1159F, and S1159P were designated as outliers by demonstrating fold response 
greater than 2 SD beyond the mean fold response of all variants studied in CFBE and 
FRT cells, and labeled as high response variants. Intermediate response variants were 
those that remained outliers when high response variants were removed from the 
comparison. All remaining variants were classified as modest response. Lines through 
data points represent the mean value ± 1 SD of each group. (D) Previously published data 
collected from FRT* cells (18, 19) of non-gating variants plotted as in A and B. (E) 
Comparison of trend lines of modest response variants identified in CFBE and FRT 






Figure 3.2 Variants located in the 6th transmembrane domain (TM6) show modest 
response to ivacaftor. 
(A) Plot of CFTR processing versus residual function for 54 variants expressed in FRT* 
cells (18) reveals heterogeneous response to 10 µM ivacaftor of partially or well 
processed low residual function missense variants (labeled). Filled green circles represent 
variants approved by FDA for ivacaftor treatment, G551D labeled in bold. (B) Western 
blot demonstrating that all TM6 variants produce mature C band CFTR protein when 
transiently expressed in HEK293 cells and representative Isc tracings of all TM6 variants 
stably expressed in CFBE cells demonstrating response to acute treatment with 10 µM 
ivacaftor, recorded as area corrected current (µA/cm2), over time, measured in minutes 
represented by tick marks in 1 min intervals. Data are representative of n ≥ 3 for each 
variant. (C) Summary data for response of TM6 variants to acute treatment with 10 µM 
ivacaftor expressed as %WT function. Box plots divide the data by quartile with the 
median value indicated by a horizontal line within the box and whiskers extend to 
minimum and maximum values. (D) Fold response for acute treatment with 10 µM 
ivacaftor calculated over residual function (10 µM forskolin) of TM6 variants compared 
to modest responsive variants identified in this study. Box plots divide the data by 
quartile with the median value indicated by a horizontal line within the box and whiskers 






Figure 3.3 Lumacaftor response correlates with residual function.  
(A) Forskolin (10 µM) stimulated CFTR function of 45 missense variants expressed in 
CF Broncial Epithelial (CFBE) cells treated for 24 h with 6 µM lumacaftor compared to 
residual forskolin (10 µM) stimulated CFTR function when incubated for 24 h with an 
equal volume DMSO. Each variant was measured n ≥ 3 and plotted as mean ± SEM. (B) 
Forskolin (5 µM) stimulated CFTR function of 18 missense variants expressed in Fisher 
Rat Thyroid (FRT) cells treated for 48 h with 3 µM lumacaftor compared to residual 
forskolin (5 µM) stimulated CFTR function when incubated for 48 h with an equal 
volume DMSO. Each variant was measured n ≥ 3 and plotted as mean ± SEM. (C) 
Separation of variants based on their fold response to lumacaftor. Response of cell lines 
expressing G91R, E92K, L138ins, L145H, and L206W were designated as outliers by 
demonstrating fold response greater than 2SD beyond the mean fold response of all 
variants studied in CFBE and FRT cells, and are labeled as high response variants. 
Intermediate response variants were those that remained outliers when high response 
variants were removed from the comparison. All remaining variants were classified as 
modest response. Lines through data points represent the mean value ±1SD of each 
group. (D) Comparison of best fit functions for variants expressed in CFBE and FRT 






Figure 3.4 TM6 variants with exceptional response to lumacaftor corresponds to 
embedded side chain orientation within channel pore. 
(A) Western blots of whole cell lysates from CF Bronchial Epithelial (CFBE) cell lines 
stably expressing TM6 variants show that lumacaftor increases the quantity of mature 
CFTR protein for all TM6 variants. (B) Isc tracings of TM6 variants reveal that a subset 
of TM6 variants have an increased response to lumacaftor (lum) recorded as area 
corrected current (µA/cm2), over time, measured in minutes represented by tick marks in 
1 min intervals. (C) Lumacaftor response of TM6 variants following 24 h treatment with 
6 µM lumacaftor or an equal volume of DMSO. Box plots divide the data by quartile 
with the median value indicated by a horizontal line within the box and whiskers extend 
to minimum and maximum values. (D) Lumacaftor response for each TM6 variant 
calculated as fold response over residual function compared to all modest response 
variants identified in CFBE cells. Box plots divide the data by quartile with the median 
value indicated by a horizontal line within the box and whiskers extend to minimum and 
maximum values. (E) Predicted orientation of TM6 residues within the CFTR 
conductance pore when in the open conformation (32). (F) Lumacaftor response relative 
to residual function for TM6 variants based on predicted orientation within the pore. Box 
plots divide the data by quartile with the median value indicated by a horizontal line 






Figure 3.5 Ivacaftor/lumacaftor (iva/lum) response correlates with residual function.  
(A) Ivacaftor (10 µM) enhanced CFTR function of 45 missense variants expressed in 
CFBE cells following for 24 h incubation with 6 µM lumacaftor compared to residual 
forskolin (10 µM) stimulated CFTR function when incubated for 24 h with DMSO. Each 
variant measured n ≥ 3 and plotted as mean ± SEM. (B) Ivacaftor (5 µM) enhanced 
CFTR function of 18 missense variants expressed in FRT cells following 24 h incubation 
with 3 µM lumacaftor compared to residual forskolin (5 µM) stimulated CFTR function 
when incubated for 24 h with DMSO. Each variant measured n ≥ 3 and plotted as mean ± 
SEM. (C) Separation of variants based on their fold response to lumacaftor. Response of 
cell lines expressing G91R, E92K, L138ins, L145H, and G551D (CFBE) were designated 
as outliers by demonstrating a fold response greater than 2 SD beyond the mean fold 
response of all variants studied in CFBE and FRT cells, and are labeled as high response 
variants. Intermediate response variants were those that remained outliers when high 
response variants were removed from the  comparison. All remaining variants were 
classified as modest response. Lines through the data points represent the mean value ± 1 
SD of each group. (D) Comparison of best fit functions for variants expressed in CFBE 







Figure 3.6 Summary of response of missense variants to CFTR modulators. 
(A) CFTR function for variants that were modest response variants for ivacaftor and 
lumacaftor when treated with forskolin (baseline), ivacaftor, lumacaftor, or iva/lum 
combination. Error bars represent ± SEM. (B) Response to ivacaftor, lumacaftor, or 
ivacaftor/lumacaftor combination for variants designated as intermediate or high response 
to ivacaftor. (C) Response to ivacaftor, lumacaftor or iva/lum combination for variants 






Figure 3.7 Combination therapy yields larger response than monotherapy across all 
response tiers. 
(A) Comparison of response trends for ivacaftor (left), lumacaftor (middle), and 
ivacaftor/lumacaftor combination (right) of all variants studied in CF Bronchial Epithelial 
(CFBE) and Fisher Rat Thyroid (FRT) cell lines. (B) Comparison of response trends for 
all 3 treatment strategies for modest response variants (left), intermediate response 






Table 3.1 Residual function and drug response for CF Bronchial Epithelial (CFBE) cell lines 
Variant HGVS cDNA 
Residual 
function (n) 
10 µM  
Ivacaftor (n) 
6 µM  
Lumacaftor (n) 
10 µM ivacaftor 
6 µM lumacaftor (n) 
P5L p.Pro5Leu c.14C>T 21.9 ± 2 (3) 25.9 ± 0.6 (3) 57.72 ± 0.6 (3) 62.2 ± 1.4 (3) 
G27R p.Gly27Arg c.79G>A 0.9 ± 0.1 (3) 0.8 ± 0 (3) 5.14 ± 0.07 (3) 5.2 ± 0.3 (3) 
W57G p.Trp57Gly c.169T>G 1.1 ± 0.1 (3) 1.3 ± 0.2 (3) 1.89 ± 0.11 (3) 2.5 ± 0.1 (3) 
G91R p.Gly91Arg c.271G>A 1.6 ± 0.2 (3) 1.7 ± 0.1 (3) 14.29 ± 0.31 (3) 21.1 ± 0.2 (3) 
Q98R p.Gln98Arg c.293A>G 4.5 ± 0.1 (3) 5.5 ± 0.2 (3) 14.32 ± 0.51 (3) 18.8 ± 0.9 (3) 
P99L p.Pro99Leu c.296C>T 3.7 ± 0.1 (3) 5.1 ± 0.6 (3) 7 ± 0.47 (3) 10.2 ± 0.3 (3) 
E116K p.Glu116Lys c.346G>A 6.9 ± 0.3 (3) 16.4 ± 0.5 (3) 11.59 ± 1.61 (3) 32.9 ± 0.5 (3) 
R117L p.Arg117Leu c.350G>T 10.2 ± 2.5 (3) 17.8 ± 1.3 (3) 13.16 ± 1.53 (3) 25.4 ± 1.3 (3) 
L138ins p.Leu138insLeu c.413_415dupTAC 1.6 ± 0.2 (3) 2.2 ± 0.2 (3) 16.1 ± 0.86 (3) 29.8 ± 1.1 (3) 
H139R p.His139Arg c.416A>G 1.5 ± 0.5 (3) 2.3 ± 0.4 (3) 2.96 ± 0.29 (3) 3.3 ± 0.9 (3) 
L145H p.Leu145His c.434T>A 5.6 ± 0.4 (3) 7.5 ± 0.4 (3) 51.48 ± 5.36 (3) 72.8 ± 3.6 (3) 
L165S p.Leu165Ser c.494T>C 1.9 ± 0.1 (3) 1.7 ± 0.1 (3) 3.1 ± 0.19 (3) 4.8 ± 0.1 (3) 
V232D p.Val232Asp c.695T>A 4.3 ± 0.4 (3) 5.5 ± 0.2 (3) 19.26 ± 2.25 (3) 30.5 ± 1.5 (3) 
F311L p.Phe311Leu c.933C>G 5.1 ± 0.6 (3) 14.7 ± 0.4 (3) 7.31 ± 0.27 (0) 25.1 ± 0.7 (3) 
R334W p.Arg334Trp c.1000C>T 2 ± 0.3 (13) 2.1 ± 0.2 (21) 2.2 ± 0.5 (8) 2.2 ± 0.3 (10) 
R334L p.Arg334Leu c.1001G>T 2.5 ± 0.2 (3) 2.6 ± 0.1 (3) 3.5 ± 0.13 (0) 4.5 ± 0.3 (3) 
R334Q p.Arg334Gln c.1001G>A 25.5 ± 1.4 (29) 34.2 ± 2.3 (30) 30.2 ± 2.1 (15) 40.9 ± 2.3 (15) 
I336K p.Ile336Lys c.1007T>A 2.3 ± 0.3 (20) 3.2 ± 0.4 (24) 9.2 ± 0.9 (13) 20.1 ± 1.5 (26) 
T338I p.Thr338Ile c.1013C>T 6.4 ± 0.3 (18) 14.2 ± 0.8 (18) 8.9 ± 0.8 (9) 20.3 ± 1.8 (9) 
I340N p.Ile340Asn c.1019T>A 12.5 ± 0.9 (33) 16.5 ± 1.6 (21) 70 ± 10.4 (20) 79.8 ± 17.7 (14) 
S341P p.Ser341Pro c.1021T>C 0.8 ± 0.1 (11) 1.5 ± 0.1 (13) 1.2 ± 0.1 (11) 2.9 ± 0.2 (13) 
M348V p.Met348Val c.1042A>G 77.8 ± 7.4 (6) 138.8 ± 7.3 (6) 103 ± 17.3 (3) 124.2 ± 56.3 (6) 
A349V p.Ala349Val c.1046C>T 45.5 ± 4.7 (13) 110.7 ± 11.2 (14) 94.9 ± 16.3 (7) 139.5 ± 32.3 (11) 
L453S p.Leu453Ser c.1358T>C 3.4 ± 0.2 (3) 3.6 ± 0.3 (3) 6.7 ± 0.3 (3) 7.6 ± 0.1 (3) 
V456A p.Val456Ala c.1367T>C 4.4 ± 0.4 (3) 6.9 ± 0 (3) 8.2 ± 0.7 (3) 11.5 ± 0.4 (3) 
E474K p.Glu474Lys c.1420G>A 1.2 ± 0.1 (3) 1 ± 0.1 (3) 3.9 ± 0.5 (3) 5.9 ± 0.2 (3) 
F508del p.Phe508del c.1521_1523del 0.5 ± 0.1 (15) 0.9 ± 0.2 (11) 1.8 ± 0.5 (10) 3.2 ± 0.7 (10) 
D513G p.Asp513Gly c.1538A>G 7 ± 1.3 (3) 10.4 ± 0.3 (3) 12.9 ± 0.6 (3) 15.2 ± 0.9 (3) 
G551D p.Gly551Asp c.1652G>A 3.2 ± 0.3 (38) 21.6 ± 1.8 (30) 4.9 ± 1.3 (14) 39.4 ± 4.2 (13) 
Y563N p.Tyr563Asn c.1687T>A 0.6 ± 0 (3) 0.7 ± 0 (3) 0.9 ± 0 (3) 1 ± 0.1 (3) 
P574H p.Pro574His c.1721C>A 4.3 ± 0.3 (3) 7.3 ± 0.3 (3) 11.5 ± 0.7 (3) 20.8 ± 0.5 (3) 
H609R p.His609Arg c.1826A>G 1.9 ± 0.1 (3) 2.5 ± 0.1 (3) 2.8 ± 0.2 (3) 3.9 ± 0.1 (3) 
A613T p.Ala613Thr c.1837G>A 2.7 ± 0.2 (3) 3.7 ± 0.1 (3) 6.1 ± 0.6 (3) 7.6 ± 0.7 (3) 
G622D p.Gly622Asp c.1865G>A 18.8 ± 0.8 (3) 24.9 ± 0.8 (3) 41.7 ± 1.7 (3) 54.7 ± 0.8 (3) 
D979V p.Asp979Val c.2936A>T 8.6 ± 1.8 (3) 19 ± 0.9 (3) 24.1 ± 5.9 (3) 72.4 ± 6.4 (3) 
A1006E p.Ala1006Glu c.3017C>A 3.9 ± 0.4 (3) 4.8 ± 0.9 (3) 6.4 ± 1.4 (3) 10.2 ± 0.5 (3) 
F1016S p.Phe1016Ser c.3047T>C 15.8 ± 1.5 (3) 24.7 ± 0.7 (3) 38.2 ± 4.7 (3) 55.4 ± 1.3 (3) 
Y1032C p.Tyr1032Cys c.3095A>G 13 ± 1.6 (3) 14.2 ± 0.4 (3) 78.5 ± 8.3 (3) 76.4 ± 5.5 (3) 
W1098C p.Trp1098Cys c.3294G>C 3.4 ± 0.3 (6) 4.1 ± 0.3 (6) 12.1 ± 0.7 (6) 19.1 ± 0.9 (6) 
S1118F p.Ser1118Phe c.3353C>T 4.8 ± 0.5 (3) 8.6 ± 0.3 (3) 8.9 ± 0.2 (3) 18.3 ± 0.4 (3) 
S1159F p.Ser1159Phe c.3476C>T 7.4 ± 1.3 (3) 43.8 ± 2.4 (3) 18.4 ± 3.8 (3) 59.5 ± 2 (3) 
S1159P p.Ser1159Pro c.3475T>C 6.4 ± 0.5 (4) 29.3 ± 1.3 (4) 10.9 ± 1.6 (4) 42.2 ± 1.4 (4) 
T1246I p.Thr1246Ile c.3737C>T 20 ± 2 (3) 52.9 ± 1.8 (3) 35.2 ± 1.8 (3) 74.7 ± 2.7 (3) 
R1283M p.Arg1283Met c.3848G>T 10.3 ± 0.9 (3) 12.5 ± 0.7 (3) 12.1 ± 1 (3) 19.1 ± 0.7 (3) 




Table 3.2 Residual function and drug response for Fisher Rat Thyroid (FRT) cell lines 
Variant HGVS cDNA 
Residual  
function (n) 
5 µM  
Ivacaftor (n) 
3 µM  
Lumacaftor (n) 
5 µM ivacaftor 
3 µM lumacaftor (n) 
P67L  p.Pro67Leu c.200C>T 10.7 ± 0.5 (3) 13.5 ± 0.7 (3) 62.1 ± 3.1 (3) 70.8 ± 4.8 (3) 
G85E p.Gly85Glu c.245G>A 0.5 ± 0 (11) 0.5 ± 0 (11) 0.6 ± 0 (11) 0.7 ± 0.1 (11) 
E92K p.Glu92Lys c.274G>A 1.3 ± 0.1 (6) 1.5 ± 0.1 (6) 14.2 ± 2.2 (6) 17.2 ± 2.6 (6) 
R117H p.Arg117His c.350G>A 20.1 ± 2.4 (6) 38.3 ± 1.9 (6) 35.6 ± 2.6 (6) 62.9 ± 2.9 (6) 
L206W p.Leu206Trp c.617T>G 7 ± 0.6 (6) 9.8 ± 0.9 (6) 60.1 ± 2.2 (6) 70.7 ± 2.3 (6) 
R334W p.Arg334Trp c.1000C>T 3.9 ± 0.5 (5) 4.9 ± 0.5 (5) 5.1 ± 0.3 (5) 6.4 ± 0.3 (5) 
T338I p.Thr338Ile c.1013C>T 7.6 ± 0.7 (6) 12 ± 0.5 (6) 13.7 ± 0.7 (6) 23.4 ± 1.1 (6) 
R347P p.Arg347Pro c.1040G>C 1 ± 0.1 (9) 1.3 ± 0.1 (9) 4 ± 0.4 (9) 5.4 ± 0.4 (9) 
A455E p.Ala455Glu c.1364C>A 5.6 ± 0.2 (3) 5.8 ± 0.2 (3) 14.8 ± 0.5 (3) 15.4 ± 0.2 (3) 
S492F p.Ser492Phe c.1475C>T 1.7 ± 0.1 (3) 1.8 ± 0.1 (3) 6.6 ± 0.1 (3) 7.2 ± 0.2 (3) 
F508del p.Phe508del c.1521_1523del 1.6 ± 0.1 (5) 2.1 ± 0.2 (5) 6.3 ± 0.4 (5) 9.6 ± 0.4 (5) 
V520F p.Val520Phe c.1558G>T 0.5 ± 0 (5) 0.5 ± 0.1 (5) 1.4 ± 0 (6) 1.5 ± 0 (6) 
G551D p.Gly551Asp c.1652G>A 4 ± 0.4 (5) 19.7 ± 0.7 (5) 9.9 ± 2 (6) 41.1 ± 0.8 (6) 
R560T p.Arg560Thr c.1679G>C 0.1 ± 0 (7) 0.1 ± 0 (7) 0.1 ± 0 (9) 0.1 ± 0 (9) 
A561E p.Ala561Glu c.1682C>A 0 ± 0 (6) 0 ± 0 (6) 0.1 ± 0 (6) 0.2 ± 0 (6) 
L1077P p.Leu1077Pro c.3230T>C 0.9 ± 0 (6) 0.8 ± 0.1 (6) 4.2 ± 0.3 (6) 3.8 ± 0.3 (6) 
M1101K p.Met1101Lys c.3302T>A 0.6 ± 0 (6) 0.5 ± 0 (6) 1.9 ± 0.1 (6) 1.7 ± 0 (6) 

















Cystic Fibrosis (CF) is an autosomal recessive disorder with nearly 90,000 
reported cases worldwide, and highest incidence occurs among white individuals of 
Northern European descent. The disease results from loss-of-function of the CF 
transmembrane conductance regulator (CFTR), a chloride and bicarbonate channel 
expressed at the apical surface of exocrine secretory epithelia. In the absence of 
functional CFTR, hyperviscous luminal secretions accumulate within respiratory, 
pancreatic, gastrointestinal and reproductive systems, ultimately leading to chronic 
inflammation, severe tissue damage, and multi-organ destruction.  
The CFTR gene was mapped in 1989, allowing extensive study and 
characterization of the biochemistry and functional role of CFTR protein. More than 
1,900 variants within CFTR have been observed to date, many of which have been shown 
to elicit one or more defects of steps comprising biogenesis, ion transport, or plasma 
membrane (PM) turnover [158–160]. CFTR variants have traditionally been grouped into 
six classes based on features associated with molecular pathogenesis: class I – defective 
protein synthesis (e.g. premature termination codons); class II – aberrant protein 
maturation and premature degradation (e.g. ‘processing’ defects); class III – abnormal 
channel regulation (e.g. ‘gating’ defects); class IV – improper formation of the channel 
pore (e.g. ‘conductance’ defects); class V – decreased levels of protein synthesis (e.g. 
splicing defects); and class VI – accelerated internalization or faulty recycling from the 
PM (e.g. ‘turnover’ defects) [www.cftr2.org] (Fig. 1).  
Although these subcategories provide a valuable means of profiling the panoply 
of CFTR abnormalities, molecular complexity of individual CFTR variants has become 
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increasingly evident. CFTR defects exist across a spectrum of severity at the molecular 
level, which correlate with a range of clinical presentations. For example, mild variants 
result in male infertility, deleterious variants result in chronic lung infection with mucus 
obstruction and progressive deterioration, whereas the most severe variants often lead to 
pancreatic and/or hepatic insufficiency. The challenge, therefore, is to understand 
mechanisms underlying various CFTR variants and develop precision medicine 
approaches tailored to all forms of the disease. This review will focus on missense 
variants (i.e. amino acid substitutions), which represent the largest category of CFTR 
defects (~40%) [3]. We will discuss strategies that have proven successful for rescuing 
CFTR function, methods for predicting therapeutic responsiveness, challenges faced with 
the current design of clinical trials, and cutting-edge tools utilized to develop more 
efficient interventions. 
 
4.2 Success story for p.G551D 
The first CFTR-targeted compound resulted from a revolutionary partnership 
between the U.S. CF Foundation and the pharmaceutical industry. Using high-
throughput, cell-based fluorescence membrane potential assays in recombinant Fischer 
rat thyroid (FRT) cells, the small molecule VX-770 (Ivacaftor, KalydecoTM) was 
discovered as a robust potentiator of gating activity in the CFTR class III variant, 
p.G551D. Ivacaftor was shown to improve multiple measures of clinical utility in patients 
carrying at least one G551D-CFTR allele, including: (1) enhanced forced expiratory 
volume in one second (FEV1), (2) increased body mass index (BMI), (3) fewer 
respiratory infections, (4) decreased hospitalizations, and (5) reduced sweat chloride 
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levels [31,161]. 
The Food and Drug Administration (FDA) approved Ivacaftor in 2012 as a 
pharmacologic treatment for CF patients 12 years and older who carry at least one copy 
of the p.G551D variant. In the years following, trials conducted in younger patients with 
the p.G551D variant (i.e. 6-12 years old), suggested that starting Ivacaftor at an earlier 
age may slow or even prevent lung disease progression [162]. Today, children two years 
and older carrying certain CFTR gating variants are approved to receive the drug, and 
longevity studies among all ages indicate clinical benefits can be maintained for years 
[161,163,164]. 
 
4.3 Ivacaftor spectrum of activity 
Based on compelling response of G551D-CFTR achieved with Ivacaftor, 
additional studies were undertaken to determine whether this compound could rescue 
other CFTR molecular phenotypes similar to p.G551D (i.e. class III or IV defects, 
including p.R117H, p.G178R, p.S549N, p.S549R, p.G551S, p.G1244E, p.G1349D, 
p.S1251N, and p.S1255P). In vitro analysis conducted on this cohort of 
gating/conductance variants revealed the compound greatly augmented resident channel 
activity [17], and subsequent clinical trial results showed significant improvement in 
FEV1, BMI, and sweat chloride levels [18,98]. As a consequence, Ivacaftor was FDA-
approved in 2014 for individuals two years and older carrying R117H-CFTR, and the 
following year, gained approval for the eight other variants listed above. 
 While this strategy has proven highly successful for a number of CFTR variants, 
similar approaches may not be sufficient to identify therapeutic interventions for all 
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missense mutations. Many CF variants exist at extremely low frequencies in the patient 
population, presenting a significant challenge to clinical evaluation. Informative human 
trials may require large numbers of subjects and controls, and are impractical for rare 
variants occurring in only 2 or 3 individuals worldwide. In general, ultra-orphan diseases 
such as CF may require alternative strategies for establishing clinical efficacy [165]. 
 
4.4 Improved understanding of CFTR variant complexity 
 To bring molecular-based therapy and precision medicine to CF patients of all 
genotypes, two significant hurdles must be overcome: (1) the large number of variants 
known to exist in CFTR, and (2) the low frequency at which many of these occur. Of the 
796 missense variants reported in the CF mutation database 
[www.genet.sickkids.on.ca/app], 81 have been functionally described, and 57 of those 
have been classified as disease-causing [www.cftr2.org]. The primary goal of the CFTR2 
project is to characterize and determine disease liability for all mutant CFTR alleles [5]. 
Distinguishing CF disease phenotypes through use of traditional categories has 
proven beneficial for studying individual CFTR variants (Fig. 1).  However, variants that 
affect several processes require a more complex classification protocol involving multiple 
categories, each of which might require a separate class of compound [28]. Missense 
variants frequently fall into the aforementioned group. In silico tools such as molecular 
modeling and dynamics simulations [114] can help predict functional consequences of 
missense variants, but are far from comprehensive.  
Sequencing of the entire CFTR coding region has become nearly commonplace 
due to substantial reduction in cost [10]. The increasing number of individuals sequenced 
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by whole-exome, whole-genome, and carrier screening, has dramatically enhanced the 
volume of sequence data derived from CF patients, asymptomatic carriers, and the 
general population. As with other genetic diseases [166], this has led to significant 
increases in the number of CFTR variants identified, necessitating more sophisticated 
methods for variant interpretation. Sequence analysis of all CFTR exons has augmented 
discovery of complex alleles, which contain multiple variants in cis. Complex alleles may 
behave differently than those with single variants in terms of function and/or drug 
response. This can lead to incorrect labeling of a variant as disease-causing until 
segregation analysis and/or functional studies exclude deleterious effects, as occurred 
with p.I148T [167]. Consequently, it may become imperative to identify all variants 
within CFTR when considering appropriate therapy for a particular CF patient. The 
establishment of large general databanks for genetic variants (ClinVar, ExAC, etc.), as 
well as expertly curated databases (e.g. CFTR2), provides important tools for 
differentiating detrimental versus benign variants based on population frequency [168]. 
 
4.5 Challenges evaluating therapeutic responsiveness 
 As the number of reported rare CFTR variants increases, model systems will 
become significantly more valuable for experimental evaluation of underlying molecular 
defects. The ability of cell-based platforms to generate robust, reliable data in an efficient 
manner will determine the rate at which new therapies can be delivered to patients. 
Investigations using an immortalized cell line (FRT) contributed to the FDA-approval 
process for Ivacaftor [17,29] and OrkambiTM (combination of Ivacaftor with the corrector 
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Lumacaftor) [30][22], and have been useful for interpreting variant phenotypes studied 
thus far [22][23]. 
In vitro systems can be utilized to identify additional variants that respond well to 
Ivacaftor alone or with Lumicaftor. For example, p.P67L is a rare variant for which 
clinical trials are less likely to occur, since there are ~240 patients worldwide 
[www.cftr2.org] who carry this defect. Notably, studies conducted in FRT cells have 
shown p.P67L responds robustly to both compounds, reaching nearly wild-type levels of 
CFTR activity [33], suggesting that patients would benefit from these drugs. Conversely, 
the p.N1303K variant is 8 times more common (reported in over 2,000 individuals), but it 
is unresponsive to VX-770 or VX-809 in FRT cells [22] and primary airway epithelia 
[49]. Although sufficient numbers of patients may be available for a robust clinical study, 
preclinical evidence strongly suggests against clinical improvement in this setting.  
 Of the missense variants reported to CFTR2 still requiring clinical classification, 
more than 500 have been noted in 10 individuals or fewer worldwide (personal 
communication, Karen S. Raraigh, Johns Hopkins). The rarity of these patients precludes 
routine collection of primary cells for functional and drug studies.  Thus, in vitro studies 
are expected to be primary generators of preliminary data for classification and analysis 
of the variants. Development of cell-based systems that more closely approximate 
primary human airway cells provides an opportunity to study rare CFTR defects and their 
response to FDA-approved compounds in a near-native context [15]. Novel strategies 
must also be employed to perform clinical efficacy trials in individuals with ultra-rare 
variants, and “N-of-1” or “N-of-a-few” are among methods currently under consideration 
[169]. 
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 In vitro experiments, in silico predictions, and pre-clinical testing are distinct 
branches of research employed for characterizing individual variants and predicting 
response to pharmacological agents. As CFTR missense variants under study are 
increasingly rare and functionally complex, strengthening the quality and quantity of 
evidence generated by these strategies will be paramount.  
 
4.6 Recent advances in model systems 
Characterization of disease-associated CFTR variants, including assessment of 
therapeutic responsiveness, has been performed in cell-based models for decades. Many 
immortalized mammalian cell lines have proven essential for distinguishing specific 
features of CFTR biogenesis, as well as mechanisms invoked by investigational 
compounds [17,105]. Recently, primary human nasal or bronchial epithelia [49,170] and 
induced pluripotent stem cells [171–173] have emerged as strong predictive tools. 
Organoids generated from patients represent another topical area of progress with the 
potential to predict individual response to a therapeutic strategy (i.e. precision medicine), 
but the validity of this postulate remains to be determined [174,175]. Additionally, six 
animal models expressing a variety of CFTR variants are now available (e.g. zebrafish, 
mouse, rat, rabbit, ferret, pig), although each has limitations regarding ease of use or 
degree to which human disease is recapitulated [14,176]. Finally, yeast phenomic 
screening has emerged as a means for discovery of gene-gene interaction networks and 
other features of CFTR class II and III variants [177–179], including identification and 
targeting of novel CFTR modulators in patient-derived epithelia [180]. 
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4.7 Future directions relevant to CF therapeutics 
Based on the success of Ivacaftor, pharmaceutical companies have begun 
developing other small molecules that partially restore CFTR function, the most 
advanced of which are second generation correctors that improve intracellular processing 
and cell surface activity of class II variants (P Grootenhuis et al, abstract 188, 30th North 
American Cystic Fibrosis Conference, Orlanda FL, October 2016), i.e. to levels above 
those achieved by the combination of Ivacaftor and Lumicaftor. There are at least 20 
clinical trials underway that utilize such pharmacological interventions, with examples of 
phase II and III studies currently under enrollment shown in Fig. 2 
[www.clinicaltrials.gov].  
The overarching goal of translational CF science is to develop therapeutic 
strategies that will benefit all individuals with CF, irrespective of genotype. Basic and 
clinical investigations are in progress to explore feasibility of innovative genetic and 
genomic medicine technologies, including transfer of nucleic acids by airway 
stem/progenitor cells [181,182], zinc finger nuclease- or CRISPR/Cas9-edited human 
pluripotent stem cells [171–173], and nanoparticles [183–185], as well as protein 
replacement via mRNA transfer [186]. Recently, enhanced adenoviral and lentiviral 
vectors were used to show functional CFTR gene delivery to airways of the CF porcine 
model [187,188], and the first lentivirus-based clinical trial is scheduled for 2017 [189]. 
 
4.8 Conclusions 
 Therapeutic benefit for individuals with CF harboring missense variants can be 
achieved by improving function of existing, partially-processed CFTR protein. As such, 
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missense alleles represent “low hanging fruit” for small molecule intervention. Variants 
that result in complete loss of CFTR protein share a potential therapeutic mechanism, in 
that they require insertion and expression of an entirely new or repaired CFTR allele. 
This is no small task, as gene transfer therapy has been in development for CF and other 
monogenic diseases since the 1990s. While the medical genetics community awaits 
technological progress to allow for sufficient CFTR gene delivery, effective therapy for 
most individuals with CF carrying missense variants is expected much sooner. 
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Figure 4.1 Classification scheme and cellular localization of CFTR variants.  
Class I and V defects result in diminished protein production, whereas class II and VI yield 
reduced stability of CFTR. In addition, class III and IV variants inhibit channel function or 
activity of cell surface associated CFTR. Molecular-based therapeutic strategies target each 
of these categories and include the following: (1) ‘synthesizers’, which rescue CFTR 
protein production (e.g. suppression of premature truncation codons, or PTCs), (2) 
‘correctors’, which augment maturation and decelerate turnover of CFTR (e.g. VX-809, 
VX-661, VX-152, VX-440, CTP-656, Miglustat, Riociguat), and (3) ‘potentiators’, which 







Figure 4.2 Examples of current phase II or III clinical trials under enrollment in the 
United States and Europe (see also www.clinicaltrials.gov).  
Various strategies outlined above intend to test safety, tolerability, and efficacy of CFTR 
modulators administered as single agents or combinatorial treatments. In the majority of 
cases, eligible patients must be homozygous or heterozygous for the most prevalent CFTR 













Chapter 5 Conclusions  
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The studies detailed here demonstrate the utility of cellular models to generate 
data that can be used to determine the functional consequence of CFTR missense 
variants, which in turn can be used to inform diagnosis of individuals carrying those 
variants. Secondly, these cell lines were used to test the response of missense variants to 
small molecule drugs to generate preliminary data which is especially useful for 
individuals carrying variants that are too rare to be tested in traditional clinical settings. 
Lastly, these studies uncovered that currently available CFTR modulators can improve 
CFTR function for the majority of missense variants, potentially allowing for modulator 
therapy to be expanded to many more individuals with CF and aiding in the development 
of future CFTR therapies.  
In vitro expression and testing of CFTR missense variants using CFBE cells has 
yielded results that are well correlated with clinical presentation of individuals carrying 
those variants. These results can be used to inform diagnosis of individuals with CF, as 
they aid in the classification of a variant as disease causing or not. This is especially 
important for rare variants as their associated clinical information is often relatively 
shallow. The functional data collected here also has the accuracy to resolve the variable 
expressivity of the CF phenotype as conferred by level of residual function. Functional 
evaluation of genetic variants by in vitro testing is wholly dependent on the strength of 
correlation with phenotype, and our CFBE system provides robust correlation with 
phenotype based on in vivo sweat chloride measurements and clinical presentation. 
We also demonstrated that these CFBE cell lines can be used to test the response 
of missense variants to the CFTR modulators ivacaftor and lumacaftor. This was first 
demonstrated by showing that the effects of those modulators on the G551D and F508del 
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variants were similar to previously published results. Subsequent testing of other 
missense variants demonstrated that ivacaftor and lumacaftor were able to increase CFTR 
activity for most missense variants. While ivacaftor and lumacaftor were developed 
against specific genetic variants, the mechanisms they improve are intrinsic to CFTR 
function itself, and thus have the potential to improve the activity of many other variants 
of CFTR protein. Variants that are specifically defective in the mechanism targeted by a 
modulator appear as high response variants demonstrating that modulators with high 
response variants are capable of targeting a specific molecular process. Developing 
compounds to target additional molecular mechanisms will require studying variants 
specifically deficient in targeted mechanisms, analogous to the development of 
potentiators against the gating variant G551D and development of correctors against the 
folding variants F508del.  
While searching for high response variants will yield novel modulators, treatment 
of individuals with CF will not be limited to those who carry variants with modulators 
developed specifically for them. Biological systems often have functional buffers such 
that function of a process or pathway can be upregulated or downregulated within certain 
limits in response to physiological needs in order to maintain functional homeostasis. 
Thus, in the same way that the function of WT CFTR protein can be increased by 
potentiators and correctors, variants that yield CFTR protein that are not deficient in 
channel gating or protein folding can also benefit from these modulators. This suggests 
that treatment of individuals with these modulators may not be limited to those carrying 
variants specifically targeted by those modulators. However, it is important to recognize 
the difference in magnitude of response when considering therapy because while CFTR 
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function may be improved at the molecular level, individuals who have very low residual 
CFTR activity may not recover enough function to demonstrate clinical utility.  
 We found that combination therapy was more effective than treatment with 
ivacaftor or lumacaftor alone for the majority of variants and was never worse than 
monotherapy. Given these findings paired with the mechanistic understanding that CFTR 
modulators act within homeostatic bounds of normal function, combination therapy is 
likely the best path to pursue for future treatment of individuals with CF, so long as they 
have variants that allow for production of CFTR protein.  
 The findings from these studies have resolved one of the key challenges to 
delivering therapy to all individuals with CF: the large number of missense variants 
found in CFTR. These findings demonstrate that all missense variants that have no defect 
in RNA processing can be targeted by small molecule therapies. Moreover, it appears that 
the response to CFTR modulators is highly predictable due to the strong correlations that 
exist between residual function and modulator enhanced function. These correlations 
suggest that it may be possible to predict clinical response based on severity of clinical 
presentation. The in vitro findings presented here predict that all variants with greater 
than 3% WT function will achieve the 10% theoretical threshold for clinical benefit, 
which correlates with variants associated with a clinical presentation of exocrine 
pancreatic sufficiency. If true, this means that pancreatic status could be used as a 
biomarker for expected therapeutic response to the ivacaftor-lumacaftor combination 
therapy.  
Despite these advances, two major goals still exist for developing therapy for 
individuals with CF. First is developing therapy for individuals who make no CFTR 
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protein, either due to large deletions of CFTR sequence or DNA sequence variants which 
introduce a PTC. Second is developing more complete combination therapies targeting 
additional molecular mechanisms to treat those individuals who are able to make CFTR 
protein so that even those who have very low residual function can benefit from 
combination therapy. Addressing those individuals who do not generate any CFTR 
protein from either of their CFTR alleles present the most significant challenge, but one 
that is not unique to CF. These types of therapies will necessitate either correction of 
genomic DNA in vivo via gene editing or some form of gene replacement therapy, both 
therapeutic avenues are under investigation for several genetic diseases. Developing more 
complete combination therapies for individuals who make CFTR protein is a process 
specific to CF. This will require a strong understanding of all of the molecular 
mechanisms involved in CFTR biogenesis, possibly by identification of archetypical 
variants for each mechanism as G551D is for channel gating. Furthermore, developing 
compounds to target additional mechanisms may be a more effective route to delivering 
therapy to more individuals with CF than developing better versions of currently 
available compounds. If these two goals can be achieved, then robust therapeutic 
intervention should be possible for all individuals with CF. 
These CFTR modulators have already had a significant impact on the CF 
community and individuals with CF are able to live longer healthier lives. The major 
limitation of these modulators appears to be their limited ability to recover lung function 
as there is likely some portion of irreversible damage done by chronic infection and 
inflammation of diseased tissues. However, beginning treatment at a younger age will 
prevent significant disease progression and further increasing quality of life and lifespan 
 113 
for individuals born with CF today. Molecular genetics research in CF has shown the 
promise and utility of understanding the consequences of DNA sequence variants for 
developing therapy targeted not only to the defective gene but to the specific molecular 
defect conferred by specific variants. 
 We hope that the findings presented here aid in delivering molecular diagnoses 
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